


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:03:56Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405968" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405968</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>canmed</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" id="cam471176" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="pmc-domain-id">1974</journal-id><journal-id journal-id-type="pmc-domain">canmed</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405968</article-id><article-id pub-id-type="pmcid-ver">PMC12405968.1</article-id><article-id pub-id-type="pmcaid">12405968</article-id><article-id pub-id-type="pmcaiid">12405968</article-id><article-id pub-id-type="pmid">40899400</article-id><article-id pub-id-type="doi">10.1002/cam4.71176</article-id><article-id pub-id-type="publisher-id">CAM471176</article-id><article-id pub-id-type="other">CAM4-2025-04-2403.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Treatment Landscape for Older Men With Metastatic Hormone&#8208;Sensitive Prostate Cancer in the United States</article-title></title-group><contrib-group><contrib id="cam471176-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhou</surname><given-names initials="B">Bo</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9440-6295</contrib-id><xref rid="cam471176-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>bo.zhou@unthsc.edu</email></address></contrib><contrib id="cam471176-cr-0002" contrib-type="author"><name name-style="western"><surname>Raval</surname><given-names initials="AD">Amit D.</given-names></name><xref rid="cam471176-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam471176-cr-0003" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yifan</given-names></name><xref rid="cam471176-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam471176-cr-0004" contrib-type="author"><name name-style="western"><surname>Korn</surname><given-names initials="MJ">Matthew J.</given-names></name><xref rid="cam471176-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cam471176-cr-0005" contrib-type="author"><name name-style="western"><surname>Sambamoorthi</surname><given-names initials="N">Nethra</given-names></name><xref rid="cam471176-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cam471176-cr-0006" contrib-type="author"><name name-style="western"><surname>Rasu</surname><given-names initials="R">Rafia</given-names></name><xref rid="cam471176-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam471176-cr-0007" contrib-type="author"><name name-style="western"><surname>Littleton</surname><given-names initials="N">Natasha</given-names></name><xref rid="cam471176-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cam471176-cr-0008" contrib-type="author"><name name-style="western"><surname>Constantinovici</surname><given-names initials="N">Niculae</given-names></name><xref rid="cam471176-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cam471176-cr-0009" contrib-type="author"><name name-style="western"><surname>Sambamoorthi</surname><given-names initials="U">Usha</given-names></name><xref rid="cam471176-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cam471176-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>University of North Texas Health Science Center</institution>
<city>Fort Worth</city>
<named-content content-type="country-part">Texas</named-content>
<country country="US">USA</country>
</aff><aff id="cam471176-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Bayer HealthCare Pharmaceuticals</institution>
<city>Whippany</city>
<named-content content-type="country-part">New Jersey</named-content>
<country country="US">USA</country>
</aff><aff id="cam471176-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Bayer AG</institution>
<city>Dexter</city>
<named-content content-type="country-part">Michigan</named-content>
<country country="US">USA</country>
</aff><aff id="cam471176-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Bayer Ltd</institution>
<city>Dublin</city>
<country country="IE">Ireland</country>
</aff><aff id="cam471176-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Bayer Consumer Care AG</institution>
<city>Basel</city>
<country country="CH">Switzerland</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Bo Zhou (<email>bo.zhou@unthsc.edu</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>14</volume><issue seq="290">17</issue><issue-id pub-id-type="pmc-issue-id">495560</issue-id><issue-id pub-id-type="doi">10.1002/cam4.v14.17</issue-id><elocation-id>e71176</elocation-id><history><date date-type="rev-recd"><day>05</day><month>7</month><year>2025</year></date><date date-type="received"><day>30</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="CAM4-14-e71176.pdf"/><self-uri content-type="pdf" xlink:href="file:CAM4-14-e71176.pdf"/><abstract><title>ABSTRACT</title><sec id="cam471176-sec-0001"><title>Objective</title><p>This study evaluated treatment patterns and factors associated with androgen deprivation therapy (ADT) intensification with androgen receptor pathway inhibitors (ARPI) and/or docetaxel among older men with mHSPC in the United States.</p></sec><sec id="cam471176-sec-0002"><title>Methods</title><p>The study utilized a retrospective cohort of 6850 older men (age&#8201;&#8805;&#8201;67&#8201;years) diagnosed with mHSPC between July 2016 and December 2019 from the Surveillance, Epidemiology, and End Results Medicare&#8208;linked database. Men must maintain continuous enrollment in Medicare fee&#8208;for&#8208;service Parts A/B/D for &#8805;&#8201;12&#8201;months before mHSPC diagnosis and &#8805;&#8201;6&#8201;months after diagnosis. Initial treatment was classified as ADT alone, ADT&#8201;+&#8201;ARPI, or ADT&#8201;+&#8201;docetaxel. Factors associated with initial treatment were examined using multivariable multinomial logistic regression.</p></sec><sec id="cam471176-sec-0003"><title>Results</title><p>The study cohort (mean age&#8201;=&#8201;76.6&#8201;years, SD&#8201;=&#8201;7.0) was mostly non&#8208;Hispanic white (77.7%), followed by non&#8208;Hispanic Black (8.4%) and Hispanic (6.5%). 30.4% received no systemic drug therapy within 6 months of mHSPC diagnosis, 47.1% received ADT alone, 14.8% received ADT&#8201;+&#8201;ARPI, and 5.9% received ADT&#8201;+&#8201;docetaxel. Among men treated with ADT, there was an increase in ADT&#8201;+&#8201;ARPI treatment from 19.0% to 30.0% and a concomitant decline in ADT monotherapy from 72.1% to 62.6% between 2017 and 2019, while ADT&#8201;+&#8201;docetaxel treatment marginally decreased from 8.8% to 7.3%. In multinomial logistic regression, men with <italic toggle="no">de novo</italic> mHSPC were more likely to receive ADT&#8201;+&#8201;docetaxel (aOR&#8201;=&#8201;2.73, 95% CI&#8201;=&#8201;[2.07, 3.60]) or ADT&#8201;+&#8201;ARPI (aOR&#8201;=&#8201;1.56, 95% CI&#8201;=&#8201;[1.32, 1.84]); whereas men with higher frailty index were less likely to receive ADT&#8201;+&#8201;docetaxel (aOR&#8201;=&#8201;0.93, 95% CI&#8201;=&#8201;[0.91, 0.95]) or ADT&#8201;+&#8201;ARPI (aOR&#8201;=&#8201;0.97, 95% CI&#8201;=&#8201;[0.96, 0.98]). Specifically, ADT&#8201;+&#8201;ARPI was less likely to be utilized among the lower socio&#8208;economic status groups.</p></sec><sec id="cam471176-sec-0004"><title>Conclusions</title><p>Three in 10 older men with mHSPC received no systemic treatment. Although there was a gradual uptake of ARPIs, monotherapy with ADT was still highly prevalent, suggesting the integration of intensified treatment is still suboptimal. Targeted interventions are necessary to enhance guideline adherence among older and frail men with mHSPC.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam471176-kwd-0001">androgen receptor pathway inhibitors (ARPI)</kwd><kwd id="cam471176-kwd-0002">metastatic hormone&#8208;sensitive prostate cancer (mHSPC)</kwd><kwd id="cam471176-kwd-0003">real&#8208;world evidence (RWE)</kwd><kwd id="cam471176-kwd-0004">SEER Medicare</kwd><kwd id="cam471176-kwd-0005">treatment intensification</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Bayer HealthCare Pharmaceuticals Inc.</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="5"/><page-count count="18"/><word-count count="8800"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.2 mode:remove_FC converted:03.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cam471176-cit-1001"><string-name name-style="western"><given-names>B.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>Raval</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, et al., &#8220;<article-title>Treatment Landscape for Older Men With Metastatic Hormone&#8208;Sensitive Prostate Cancer in the United States</article-title>,&#8221; <source>Cancer Medicine</source><volume>14</volume>, no. <issue>17</issue> (<year>2025</year>): <elocation-id>e71176</elocation-id>, <pub-id pub-id-type="doi">10.1002/cam4.71176</pub-id>.<pub-id pub-id-type="pmid">40899400</pub-id><pub-id pub-id-type="pmcid">PMC12405968</pub-id></mixed-citation>
</p><fn-group id="cam471176-ntgp-0001"><fn fn-type="funding" id="cam471176-note-0001"><p>
<bold>Funding:</bold> This research project was funded by Bayer HealthCare Pharmaceuticals Inc.</p></fn></fn-group></notes></front><body id="cam471176-body-0001"><sec id="cam471176-sec-0005"><label>1</label><title>Introduction</title><p>Prostate cancer (PC) is the second leading cause of cancer&#8208;related death among men in the United States (US). According to recent national estimates, 288,300 new cases of PC were estimated to be diagnosed in 2023, and 3.5 million cancer survivors had a history of PC in 2020 [<xref rid="cam471176-bib-0001" ref-type="bibr">1</xref>, <xref rid="cam471176-bib-0002" ref-type="bibr">2</xref>]. Nearly 8% of new cases were diagnosed with metastases within the US [<xref rid="cam471176-bib-0001" ref-type="bibr">1</xref>]. It was estimated that 120,368 men with PC had metastases as of 2018. Nearly 55% of metastatic diseases had de novo metastases/synchronous (i.e., at diagnosis of PC) metastatic hormone&#8208;sensitive PC (mHSPC), while the remaining 45% progressed from non&#8208;metastatic to metastases prior to developing castration resistance [<xref rid="cam471176-bib-0003" ref-type="bibr">3</xref>].</p><p>The incidence rates of metastatic PC increased significantly between 2010 and 2018 among men of all age groups [<xref rid="cam471176-bib-0004" ref-type="bibr">4</xref>]. For example, among men aged 75&#8201;years or older, the incidence rate of metastatic PC increased from an annual percentage of 6.5% in 2011 to 7.8% in 2018. Among men aged 55&#8211;69years, there was a 92% increase in metastatic PC [<xref rid="cam471176-bib-0005" ref-type="bibr">5</xref>]. Hormone&#8208;sensitive PC (HSPC) is the predominant etiology when patients present with metastatic disease at diagnosis [<xref rid="cam471176-bib-0006" ref-type="bibr">6</xref>].</p><p>Survival of men with mHSPC has dramatically improved over recent years due to the evolving treatment landscape [<xref rid="cam471176-bib-0007" ref-type="bibr">7</xref>]. Before 2014, the mainstay of treatment for mHSPC was androgen deprivation therapy (ADT) through medications or surgical procedures. Since 2015, multiple clinical trials have shown that doublet or triplet therapy for mHSPC is associated with longer survival. For example, CHAARTED and STAMPEDE trials demonstrated the benefits of combining docetaxel with ADT in progression&#8208;free survival (PFS) and overall survival (OS) [<xref rid="cam471176-bib-0008" ref-type="bibr">8</xref>, <xref rid="cam471176-bib-0009" ref-type="bibr">9</xref>]. Several trials showed that adding androgen receptor pathway inhibitors (ARPIs), a class of drug that inhibits tumor growth by blocking androgen receptor pathways, to ADT can also improve OS. The doublet therapy included ADT&#8201;+&#8201;abiraterone (STAMPEDE and LATITUDE), ADT&#8201;+&#8201;apalutamide (TITAN) and ADT&#8201;+&#8201;enzalutamide (ENZAMET and ARCHES) [<xref rid="cam471176-bib-0010" ref-type="bibr">10</xref>, <xref rid="cam471176-bib-0011" ref-type="bibr">11</xref>, <xref rid="cam471176-bib-0012" ref-type="bibr">12</xref>]. Other randomized controlled trials (RCTs) have shown that triplet therapy (ARPI + ADT+ Docetaxel) compared to doublet therapy (ADT&#8201;+&#8201;Docetaxel) further improved OS among men with mHSPC [<xref rid="cam471176-bib-0013" ref-type="bibr">13</xref>, <xref rid="cam471176-bib-0014" ref-type="bibr">14</xref>].</p><p>Given the benefits of intensification, ADT monotherapy is often considered insufficient [<xref rid="cam471176-bib-0015" ref-type="bibr">15</xref>]. Current clinical guidelines recommend doublet or triplet therapies for men with mHSPC as the standard of care [<xref rid="cam471176-bib-0016" ref-type="bibr">16</xref>]. However, findings from studies using real&#8208;world data indicate that many men with mHSPC still receive ADT monotherapy. For example, Ryan et&#160;al. examined the treatment patterns in 6517 men with mHSPC (Optum database of Commercial and Medicare Advantage enrollees) between 2014 and 2019 and 13,324 men with mHSPC (Medicare fee&#8208;for&#8208;service (FFS) enrollees' data) between 2014 and 2017. Findings showed that only 62% of Optum and 52% of Medicare FFS enrollees received any therapy for mHSPC, with ADT alone being utilized in 43% and 46% of Optum and Medicare FFS enrollees, respectively [<xref rid="cam471176-bib-0017" ref-type="bibr">17</xref>]. Freedland et&#160;al. also examined the utilization patterns in 1395 men with mHSPC who received at least one treatment modality using data from the Veteran Healthcare Administration (VHA) between 2014 and 2018. The authors found that nearly two&#8208;thirds (63%) of men received ADT only, followed by ADT in combination with ARIs (24%), docetaxel (8%), and abiraterone (5%) [<xref rid="cam471176-bib-0018" ref-type="bibr">18</xref>]. Recently, Heath et&#160;al. utilized the IQVIA claims database of 109,607 men with mHSPC identified from 2015 to 2021. Although the authors noted ADT alone being utilized in almost half of the men with mHSPC, there was an increase in the uptake of abiraterone, enzalutamide, or apalutamide over the years 2015 to 2021 [<xref rid="cam471176-bib-0019" ref-type="bibr">19</xref>].</p><p>While these studies have highlighted the high prevalence of ADT monotherapy, they focused only on Medicare Advantage enrollees or Medicare fee&#8208;for&#8208;service enrollees using only claims data or relied on VHA data. To fill in the knowledge gap, we evaluated the treatment patterns and factors associated with intensification beyond ADT among older men (aged 67&#8201;years and above) with mHSPC in the US using the Surveillance, Epidemiology, and End Results (SEER) Medicare linked data. This study makes a unique contribution by linking two large population&#8208;based databases, namely, cancer surveillance registry (SEER) and FFS Medicare claims. The combined dataset encompassed a diverse range of racial and ethnic groups and provided comprehensive information on patient demographics, cancer diagnostics, and treatment patterns.</p></sec><sec sec-type="methods" id="cam471176-sec-0006"><label>2</label><title>Methods</title><sec id="cam471176-sec-0007"><label>2.1</label><title>Study Design</title><p>This study has been exempted from the North Texas Regional Institutional Review Board (NTRIRB) for ethical approval. Waiver of informed consent was approved by the NTRIRB for this observational study using secondary data.</p><p>This observational retrospective cohort study utilized the SEER&#8208;Medicare linked database over a 6&#8208;year period from 2015 to 2020. The study cohort comprised male Medicare beneficiaries aged 67&#8201;years and older at the time of their diagnosis of mHSPC. The diagnosis timeframe spanned from July 2016 to December 2019, selected to coincide with the reporting period of clinical trial findings related to ADT intensification. The index date was defined as the mHSPC diagnosis date, which was extracted from both the registry and claims databases. A look&#8208;back period of 18&#8201;months was applied for patients diagnosed with stages I&#8208;III to identify hormone&#8208;sensitive patients and exclude individuals with metastatic castration&#8208;resistant PC (mCRPC). A 12&#8208;month baseline period prior to the index date allowed for the identification of chronic conditions, medication use, polypharmacy, healthcare resource utilization, and associated costs using Medicare claims data. The treatment identification period will span 6 months following the index date, including the diagnosis date, as previous research indicates an average treatment initiation time of approximately 51&#8201;days. An additional 4&#8208;month window will be included to capture combination therapies. The follow&#8208;up period will end at the earliest of the last date of insurance disenrollment, patient death, or December 31, 2020, with a minimum expected follow&#8208;up of 12&#8201;months post diagnosis, unless the patient dies earlier.</p></sec><sec id="cam471176-sec-0008"><label>2.2</label><title>Data Source</title><p>Data sources for this study included: (1) SEER cancer data; (2) Medicare Master Beneficiary Summary Files (MBSF); (3) Medicare claims files. The SEER registry data contains clinical, demographic, and cause of death information for cancer cases diagnosed within various locations across the US, representing approximately 34% of the US population. The MBSF files include demographic and enrollment details for each Medicare beneficiary. The Medicare claims files were submitted by various providers and healthcare facilities and contribute detailed billing and service information, including diagnosis and procedure codes, prescription medication information, provider information, service dates, and payment details.</p></sec><sec id="cam471176-sec-0009"><label>2.3</label><title>Study Cohort</title><p>The study cohort comprised 6850 men diagnosed with mHSPC between July 2016 and December 2019, identified from a larger dataset of 655,074 cancer cases recorded in the SEER Registry from 2008 to 2019 (Appendix&#160;<xref rid="cam471176-app-0001" ref-type="app">1</xref>). We identified mHSPC from two separate sources: (a) men initially diagnosed with metastatic PC (Combined Summary Stage&#8212;distant: spread to distant lymph nodes or metastases) in the SEER registry were considered to have de novo mHSPC; (b) to identify recurrent mHSPC cases, a modified version of the published algorithm by Freedland et&#160;al. was employed (Appendix&#160;<xref rid="cam471176-app-0002" ref-type="app">2</xref>). This algorithm effectively accommodates scenarios where repeated Prostate&#8208;Specific Antigen (PSA) measurements are unavailable, although it is noted that fewer than 1% of PC patients are identified as having mHSPC based solely on PSA values [<xref rid="cam471176-bib-0020" ref-type="bibr">20</xref>].</p><p>Additionally, men must be 67&#8201;years and older at mHSPC diagnosis and had uninterrupted FFS Medicare coverage (Parts A, B, and D) for at least 12&#8201;months prior to diagnosis and 12&#8201;months following diagnosis. The age cutoff was chosen to ensure a sufficient look&#8208;back period, given that Medicare eligibility begins at age 65. The enrollment criteria were crucial for analyzing treatment patterns and healthcare resource utilization. Men with any Health Maintenance Organization (HMO) coverage during these periods were excluded, as their medical claims were not available. Men with multiple cancer diagnoses or who received hospice care prior to mHSPC diagnosis were excluded to ensure that treatment effects can be accurately attributed to mHSPC.</p></sec><sec id="cam471176-sec-0010"><label>2.4</label><title>Study Measures</title><sec id="cam471176-sec-0011"><label>2.4.1</label><title>Dependent Variable: <styled-content style="fixed-case" toggle="no">mHSPC</styled-content> Initial Treatment</title><p>Treatment within 6&#8201;months of mHSPC was identified from Medicare claims and classified into three categories: (1) ADT&#8201;+&#8201;ARPIs, which included patients who had claims for ARPIs within 30&#8201;days prior to or 4 months after the initiation of ADT. Due to limited claims data availability (up to December 2020) following the 2019 approvals of apalutamide and enzalutamide, only descriptive analyses will be conducted for this group. (2) ADT&#8201;+&#8201;docetaxel, which consisted of patients with claims for docetaxel within 30&#8201;days prior to or 4 months after ADT initiation for de novo mHSPC, or at any time for recurrent mHSPC. (3) ADT monotherapy, which included patients treated exclusively with ADT or in combination with bicalutamide, flutamide, or nilutamide. Patients receiving triplet therapy were excluded from our analysis due to the small number of individuals treated (<italic toggle="yes">N</italic>&#8201;=&#8201;36).</p></sec><sec id="cam471176-sec-0012"><label>2.4.2</label><title>Independent Variables</title><p>Baseline characteristics comprised age at diagnosis, race and ethnicity, marital status, region of residence, type of metastasis at diagnosis, number of chronic conditions, and the year of diagnosis. Specifically, age was recorded as a continuous variable reflecting the patient's age at the time of diagnosis, while race and ethnicity were categorized into groups such as White, Black or African American, Hispanic or Latino, Asian, and Other. Marital status was also categorized, encompassing options like Single, Married, Divorced, and Widowed, to capture potential social support differences. Additionally, region was classified into four geographic areas: Northeast, Midwest, South, and West. The analysis distinguishes between de novo metastatic cases, indicating newly diagnosed metastatic disease, and recurrent mHSPC, reflecting a recurrence of previously treated non&#8208;metastatic disease. The total number of chronic conditions reported by patients serves as a continuous variable, providing insight into their overall health status. Lastly, the year of diagnosis was included as a continuous variable to account for potential temporal trends in treatment and outcomes.</p><p>In addition to individual characteristics, this study incorporates census&#8208;tract&#8208;level social determinants of health (SDoH) through the Yost Index, a composite measure of socioeconomic status. The Yost Index comprises seven census variables: average educational level, median income, poverty rate, median housing value, median rent, unemployment rate, and employment mix. These variables collectively provide a nuanced understanding of the economic context in which patients reside, highlighting how social determinants may influence health outcomes in mHSPC patients. By integrating these individual and contextual factors, the study aims to identify disparities and better understand the complex interplay of personal and socioeconomic influences on the management of mHSPC.</p></sec><sec id="cam471176-sec-0013"><label>2.4.3</label><title>Other Variable: Next Line of Treatment After Index Therapy</title><p>The next line of therapy was defined as the first medication (docetaxel, abiraterone, apalutamide, or enzalutamide) started after the first 6&#8208;month initial treatment identification period, which was not included in the index treatment. Time to next line of therapy was defined as the duration from ADT initiation to the initiation of the next treatment (docetaxel or ARPI) for men who received ADT monotherapy as index treatment; for those who received intensified therapy with docetaxel or ARPI in index therapy, time to next therapy was defined as the time from ADT intensification (initiation of docetaxel or ARPI in 6&#8208;month treatment identification period) to start the next line of therapy. For example, for men who received abiraterone as initial treatment and transitioned to enzalutamide, time to next therapy was defined as the months between abiraterone initiation date and enzalutamide start date.</p></sec></sec><sec id="cam471176-sec-0014"><label>2.5</label><title>Statistical Analyses</title><p>Descriptive statistics were reported to summarize the demographics, clinical characteristics, and prior treatment histories of the overall study population and the different treatment groups. The Pearson chi&#8208;square test was used to examine factors associated with mHSPC treatment. We applied multinomial logistic regression analysis to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) of receiving ADT intensification with ARPI or chemotherapy versus ADT alone, while controlling for age, gender, baseline health conditions, and SDoH.</p></sec></sec><sec sec-type="results" id="cam471176-sec-0015"><label>3</label><title>Results</title><sec id="cam471176-sec-0016"><label>3.1</label><title>Characteristics of the Study Cohort</title><p>Characteristics of the 6850 men in our study cohort were summarized in Table&#160;<xref rid="cam471176-tbl-0001" ref-type="table">1</xref>. The average age at mHSPC diagnosis was 76.6&#8201;years (SD&#8201;=&#8201;7.0). 77.7% of men in the study cohort were non&#8208;Hispanic white (NHW), 8.4% were non&#8208;Hispanic black (NHB), and 6.5% were Hispanic. Additionally, 54.1% were married at PC diagnosis, 17.3% were dual eligible low&#8208;income beneficiaries, 1.7% were in a rural area, and 9.3% were frail as measured by the claim&#8208;based frailty index.</p><table-wrap position="float" id="cam471176-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics of study cohort: stratified by de novo and recurrent mHSPC.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Characteristics</th><th align="center" colspan="2" valign="bottom" rowspan="1">Overall</th><th align="center" colspan="2" valign="bottom" rowspan="1">De novo metastases</th><th align="center" colspan="2" valign="bottom" rowspan="1">Recurrent metastases</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>/mean (SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Col %/median (IQR)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>/mean (SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Col %/median (IQR)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>/mean (SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Col %/median (IQR)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Cohort size</td><td align="center" valign="top" rowspan="1" colspan="1">6850</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4042</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2808</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Time to treatment from PC, in months</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PC to mHSPC diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">20.95 (36.07)</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 (0.00&#8211;31.04)</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">51.32 (40.05)</td><td align="center" valign="top" rowspan="1" colspan="1">48.03 (9.04&#8211;86.05)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">mHSPC to ADT initiation</td><td align="center" valign="top" rowspan="1" colspan="1">1.61 (1.18)</td><td align="center" valign="top" rowspan="1" colspan="1">1.32 (0.79&#8211;2.07)</td><td align="center" valign="top" rowspan="1" colspan="1">1.65 (1.11)</td><td align="center" valign="top" rowspan="1" colspan="1">1.38 (0.89&#8211;2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1.51 (1.32)</td><td align="center" valign="top" rowspan="1" colspan="1">1.12 (0.59&#8211;1.94)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">mHSPC to ADT intensification</td><td align="center" valign="top" rowspan="1" colspan="1">2.69 (1.38)</td><td align="center" valign="top" rowspan="1" colspan="1">2.43 (1.63&#8211;3.62)</td><td align="center" valign="top" rowspan="1" colspan="1">2.74 (1.35)</td><td align="center" valign="top" rowspan="1" colspan="1">2.47 (1.71&#8211;3.65)</td><td align="center" valign="top" rowspan="1" colspan="1">2.54 (1.44)</td><td align="center" valign="top" rowspan="1" colspan="1">2.24 (1.45&#8211;3.39)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ADT initiation to ADT intensification</td><td align="center" valign="top" rowspan="1" colspan="1">1.26 (1.36)</td><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.23&#8211;1.94)</td><td align="center" valign="top" rowspan="1" colspan="1">1.25 (1.32)</td><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.26&#8211;1.91)</td><td align="center" valign="top" rowspan="1" colspan="1">1.29 (1.49)</td><td align="center" valign="top" rowspan="1" colspan="1">1.02 (0.13&#8211;2.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at mHSPC diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">76.6 (7.0)</td><td align="center" valign="top" rowspan="1" colspan="1">75 (71&#8211;81)</td><td align="center" valign="top" rowspan="1" colspan="1">77.43 (7.14)</td><td align="center" valign="top" rowspan="1" colspan="1">76 (71&#8211;83)</td><td align="center" valign="top" rowspan="1" colspan="1">75.4 (6.35)</td><td align="center" valign="top" rowspan="1" colspan="1">74 (70&#8211;79)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at mHSPC diagnosis (categorized)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">67&#8211;69</td><td align="center" valign="top" rowspan="1" colspan="1">1142</td><td align="center" valign="top" rowspan="1" colspan="1">16.7</td><td align="center" valign="top" rowspan="1" colspan="1">596</td><td align="center" valign="top" rowspan="1" colspan="1">14.7</td><td align="center" valign="top" rowspan="1" colspan="1">546</td><td align="center" valign="top" rowspan="1" colspan="1">19.4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">70&#8211;74</td><td align="center" valign="top" rowspan="1" colspan="1">1946</td><td align="center" valign="top" rowspan="1" colspan="1">28.4</td><td align="center" valign="top" rowspan="1" colspan="1">1040</td><td align="center" valign="top" rowspan="1" colspan="1">25.7</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">32.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">75&#8211;79</td><td align="center" valign="top" rowspan="1" colspan="1">1593</td><td align="center" valign="top" rowspan="1" colspan="1">23.3</td><td align="center" valign="top" rowspan="1" colspan="1">922</td><td align="center" valign="top" rowspan="1" colspan="1">22.8</td><td align="center" valign="top" rowspan="1" colspan="1">671</td><td align="center" valign="top" rowspan="1" colspan="1">23.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">80 or older</td><td align="center" valign="top" rowspan="1" colspan="1">2169</td><td align="center" valign="top" rowspan="1" colspan="1">31.7</td><td align="center" valign="top" rowspan="1" colspan="1">1484</td><td align="center" valign="top" rowspan="1" colspan="1">36.7</td><td align="center" valign="top" rowspan="1" colspan="1">685</td><td align="center" valign="top" rowspan="1" colspan="1">24.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race and ethnicity</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NHW</td><td align="center" valign="top" rowspan="1" colspan="1">5323</td><td align="center" valign="top" rowspan="1" colspan="1">77.7</td><td align="center" valign="top" rowspan="1" colspan="1">3128</td><td align="center" valign="top" rowspan="1" colspan="1">77.4</td><td align="center" valign="top" rowspan="1" colspan="1">2195</td><td align="center" valign="top" rowspan="1" colspan="1">78.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NHB</td><td align="center" valign="top" rowspan="1" colspan="1">574</td><td align="center" valign="top" rowspan="1" colspan="1">8.4</td><td align="center" valign="top" rowspan="1" colspan="1">341</td><td align="center" valign="top" rowspan="1" colspan="1">8.4</td><td align="center" valign="top" rowspan="1" colspan="1">233</td><td align="center" valign="top" rowspan="1" colspan="1">8.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">447</td><td align="center" valign="top" rowspan="1" colspan="1">6.5</td><td align="center" valign="top" rowspan="1" colspan="1">280</td><td align="center" valign="top" rowspan="1" colspan="1">6.9</td><td align="center" valign="top" rowspan="1" colspan="1">167</td><td align="center" valign="top" rowspan="1" colspan="1">5.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other/unknown</td><td align="center" valign="top" rowspan="1" colspan="1">506</td><td align="center" valign="top" rowspan="1" colspan="1">7.4</td><td align="center" valign="top" rowspan="1" colspan="1">293</td><td align="center" valign="top" rowspan="1" colspan="1">7.2</td><td align="center" valign="top" rowspan="1" colspan="1">213</td><td align="center" valign="top" rowspan="1" colspan="1">7.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marital status at PC diagnosis<xref rid="cam471176-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Married</td><td align="center" valign="top" rowspan="1" colspan="1">3706</td><td align="center" valign="top" rowspan="1" colspan="1">54.1</td><td align="center" valign="top" rowspan="1" colspan="1">2155</td><td align="center" valign="top" rowspan="1" colspan="1">53.3</td><td align="center" valign="top" rowspan="1" colspan="1">1551</td><td align="center" valign="top" rowspan="1" colspan="1">55.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Widowed/separated/divorced</td><td align="center" valign="top" rowspan="1" colspan="1">2191</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">1310</td><td align="center" valign="top" rowspan="1" colspan="1">32.4</td><td align="center" valign="top" rowspan="1" colspan="1">881</td><td align="center" valign="top" rowspan="1" colspan="1">31.4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Never married</td><td align="center" valign="top" rowspan="1" colspan="1">953</td><td align="center" valign="top" rowspan="1" colspan="1">13.9</td><td align="center" valign="top" rowspan="1" colspan="1">577</td><td align="center" valign="top" rowspan="1" colspan="1">14.3</td><td align="center" valign="top" rowspan="1" colspan="1">376</td><td align="center" valign="top" rowspan="1" colspan="1">13.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Region</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Northeast</td><td align="center" valign="top" rowspan="1" colspan="1">2449</td><td align="center" valign="top" rowspan="1" colspan="1">35.8</td><td align="center" valign="top" rowspan="1" colspan="1">1428</td><td align="center" valign="top" rowspan="1" colspan="1">35.3</td><td align="center" valign="top" rowspan="1" colspan="1">1021</td><td align="center" valign="top" rowspan="1" colspan="1">36.4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">South</td><td align="center" valign="top" rowspan="1" colspan="1">1761</td><td align="center" valign="top" rowspan="1" colspan="1">25.7</td><td align="center" valign="top" rowspan="1" colspan="1">1029</td><td align="center" valign="top" rowspan="1" colspan="1">25.5</td><td align="center" valign="top" rowspan="1" colspan="1">732</td><td align="center" valign="top" rowspan="1" colspan="1">26.1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Midwest</td><td align="center" valign="top" rowspan="1" colspan="1">482</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">291</td><td align="center" valign="top" rowspan="1" colspan="1">7.2</td><td align="center" valign="top" rowspan="1" colspan="1">191</td><td align="center" valign="top" rowspan="1" colspan="1">6.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">West</td><td align="center" valign="top" rowspan="1" colspan="1">2158</td><td align="center" valign="top" rowspan="1" colspan="1">31.5</td><td align="center" valign="top" rowspan="1" colspan="1">1294</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">864</td><td align="center" valign="top" rowspan="1" colspan="1">30.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rurality</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Rural</td><td align="center" valign="top" rowspan="1" colspan="1">119</td><td align="center" valign="top" rowspan="1" colspan="1">1.7</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">1.7</td><td align="center" valign="top" rowspan="1" colspan="1">51</td><td align="center" valign="top" rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Not rural</td><td align="center" valign="top" rowspan="1" colspan="1">6731</td><td align="center" valign="top" rowspan="1" colspan="1">98.3</td><td align="center" valign="top" rowspan="1" colspan="1">3974</td><td align="center" valign="top" rowspan="1" colspan="1">98.3</td><td align="center" valign="top" rowspan="1" colspan="1">2757</td><td align="center" valign="top" rowspan="1" colspan="1">98.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dual eligibility (low&#8208;income) Yes/No</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Dual eligible</td><td align="center" valign="top" rowspan="1" colspan="1">1188</td><td align="center" valign="top" rowspan="1" colspan="1">17.3</td><td align="center" valign="top" rowspan="1" colspan="1">788</td><td align="center" valign="top" rowspan="1" colspan="1">19.5</td><td align="center" valign="top" rowspan="1" colspan="1">400</td><td align="center" valign="top" rowspan="1" colspan="1">14.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Not dual eligible</td><td align="center" valign="top" rowspan="1" colspan="1">5662</td><td align="center" valign="top" rowspan="1" colspan="1">82.7</td><td align="center" valign="top" rowspan="1" colspan="1">3254</td><td align="center" valign="top" rowspan="1" colspan="1">80.5</td><td align="center" valign="top" rowspan="1" colspan="1">2408</td><td align="center" valign="top" rowspan="1" colspan="1">85.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">YOST index quantiles</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">198</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td><td align="center" valign="top" rowspan="1" colspan="1">108</td><td align="center" valign="top" rowspan="1" colspan="1">2.7</td><td align="center" valign="top" rowspan="1" colspan="1">90</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 1</td><td align="center" valign="top" rowspan="1" colspan="1">789</td><td align="center" valign="top" rowspan="1" colspan="1">11.5</td><td align="center" valign="top" rowspan="1" colspan="1">491</td><td align="center" valign="top" rowspan="1" colspan="1">12.1</td><td align="center" valign="top" rowspan="1" colspan="1">298</td><td align="center" valign="top" rowspan="1" colspan="1">10.6</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 2</td><td align="center" valign="top" rowspan="1" colspan="1">953</td><td align="center" valign="top" rowspan="1" colspan="1">13.9</td><td align="center" valign="top" rowspan="1" colspan="1">585</td><td align="center" valign="top" rowspan="1" colspan="1">14.5</td><td align="center" valign="top" rowspan="1" colspan="1">368</td><td align="center" valign="top" rowspan="1" colspan="1">13.1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 3</td><td align="center" valign="top" rowspan="1" colspan="1">1144</td><td align="center" valign="top" rowspan="1" colspan="1">16.7</td><td align="center" valign="top" rowspan="1" colspan="1">699</td><td align="center" valign="top" rowspan="1" colspan="1">17.3</td><td align="center" valign="top" rowspan="1" colspan="1">445</td><td align="center" valign="top" rowspan="1" colspan="1">15.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 4</td><td align="center" valign="top" rowspan="1" colspan="1">1503</td><td align="center" valign="top" rowspan="1" colspan="1">21.9</td><td align="center" valign="top" rowspan="1" colspan="1">893</td><td align="center" valign="top" rowspan="1" colspan="1">22.1</td><td align="center" valign="top" rowspan="1" colspan="1">610</td><td align="center" valign="top" rowspan="1" colspan="1">21.7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 5</td><td align="center" valign="top" rowspan="1" colspan="1">2263</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">1266</td><td align="center" valign="top" rowspan="1" colspan="1">31.3</td><td align="center" valign="top" rowspan="1" colspan="1">997</td><td align="center" valign="top" rowspan="1" colspan="1">35.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PSA at PC diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">3385</td><td align="center" valign="top" rowspan="1" colspan="1">49.4</td><td align="center" valign="top" rowspan="1" colspan="1">1818</td><td align="center" valign="top" rowspan="1" colspan="1">45</td><td align="center" valign="top" rowspan="1" colspan="1">1567</td><td align="center" valign="top" rowspan="1" colspan="1">55.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;&#8201;4</td><td align="center" valign="top" rowspan="1" colspan="1">199</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td><td align="center" valign="top" rowspan="1" colspan="1">87</td><td align="center" valign="top" rowspan="1" colspan="1">2.2</td><td align="center" valign="top" rowspan="1" colspan="1">112</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">4&#8211;10</td><td align="center" valign="top" rowspan="1" colspan="1">996</td><td align="center" valign="top" rowspan="1" colspan="1">14.5</td><td align="center" valign="top" rowspan="1" colspan="1">318</td><td align="center" valign="top" rowspan="1" colspan="1">7.9</td><td align="center" valign="top" rowspan="1" colspan="1">678</td><td align="center" valign="top" rowspan="1" colspan="1">24.1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">11&#8211;20</td><td align="center" valign="top" rowspan="1" colspan="1">580</td><td align="center" valign="top" rowspan="1" colspan="1">8.5</td><td align="center" valign="top" rowspan="1" colspan="1">308</td><td align="center" valign="top" rowspan="1" colspan="1">7.6</td><td align="center" valign="top" rowspan="1" colspan="1">272</td><td align="center" valign="top" rowspan="1" colspan="1">9.7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&gt;&#8201;20</td><td align="center" valign="top" rowspan="1" colspan="1">1690</td><td align="center" valign="top" rowspan="1" colspan="1">24.7</td><td align="center" valign="top" rowspan="1" colspan="1">1511</td><td align="center" valign="top" rowspan="1" colspan="1">37.4</td><td align="center" valign="top" rowspan="1" colspan="1">179</td><td align="center" valign="top" rowspan="1" colspan="1">6.4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PSA Level based on non&#8208;missing observations</td><td align="center" valign="top" rowspan="1" colspan="1">41.1 (39.2)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (8&#8211;98)</td><td align="center" valign="top" rowspan="1" colspan="1">56.27 (39.61)</td><td align="center" valign="top" rowspan="1" colspan="1">55.95 (14.3&#8211;98)</td><td align="center" valign="top" rowspan="1" colspan="1">13.82 (17.79)</td><td align="center" valign="top" rowspan="1" colspan="1">7.9 (5.6&#8211;13.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gleason score at PC diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">3853</td><td align="center" valign="top" rowspan="1" colspan="1">56.2</td><td align="center" valign="top" rowspan="1" colspan="1">2398</td><td align="center" valign="top" rowspan="1" colspan="1">59.3</td><td align="center" valign="top" rowspan="1" colspan="1">1455</td><td align="center" valign="top" rowspan="1" colspan="1">51.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Glsn LE7</td><td align="center" valign="top" rowspan="1" colspan="1">1114</td><td align="center" valign="top" rowspan="1" colspan="1">16.3</td><td align="center" valign="top" rowspan="1" colspan="1">303</td><td align="center" valign="top" rowspan="1" colspan="1">7.5</td><td align="center" valign="top" rowspan="1" colspan="1">811</td><td align="center" valign="top" rowspan="1" colspan="1">28.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Glsn GE8</td><td align="center" valign="top" rowspan="1" colspan="1">1883</td><td align="center" valign="top" rowspan="1" colspan="1">27.5</td><td align="center" valign="top" rowspan="1" colspan="1">1341</td><td align="center" valign="top" rowspan="1" colspan="1">33.2</td><td align="center" valign="top" rowspan="1" colspan="1">542</td><td align="center" valign="top" rowspan="1" colspan="1">19.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gleason clinical score based on non&#8208;missing observations</td><td align="center" valign="top" rowspan="1" colspan="1">8 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (7&#8211;9)</td><td align="center" valign="top" rowspan="1" colspan="1">8.48 (0.99)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (8&#8211;9)</td><td align="center" valign="top" rowspan="1" colspan="1">7.44 (1.07)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (7&#8211;8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Risk group based on Gleason score and PSA values<xref rid="cam471176-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">3161</td><td align="center" valign="top" rowspan="1" colspan="1">46.1</td><td align="center" valign="top" rowspan="1" colspan="1">1723</td><td align="center" valign="top" rowspan="1" colspan="1">42.6</td><td align="center" valign="top" rowspan="1" colspan="1">1438</td><td align="center" valign="top" rowspan="1" colspan="1">51.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Not high risk</td><td align="center" valign="top" rowspan="1" colspan="1">1458</td><td align="center" valign="top" rowspan="1" colspan="1">21.3</td><td align="center" valign="top" rowspan="1" colspan="1">531</td><td align="center" valign="top" rowspan="1" colspan="1">13.1</td><td align="center" valign="top" rowspan="1" colspan="1">927</td><td align="center" valign="top" rowspan="1" colspan="1">33</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High risk</td><td align="center" valign="top" rowspan="1" colspan="1">2231</td><td align="center" valign="top" rowspan="1" colspan="1">32.6</td><td align="center" valign="top" rowspan="1" colspan="1">1788</td><td align="center" valign="top" rowspan="1" colspan="1">44.2</td><td align="center" valign="top" rowspan="1" colspan="1">443</td><td align="center" valign="top" rowspan="1" colspan="1">15.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Claim&#8208;based spread of Metastasis<xref rid="cam471176-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bone only</td><td align="center" valign="top" rowspan="1" colspan="1">2969</td><td align="center" valign="top" rowspan="1" colspan="1">43.3</td><td align="center" valign="top" rowspan="1" colspan="1">1727</td><td align="center" valign="top" rowspan="1" colspan="1">42.7</td><td align="center" valign="top" rowspan="1" colspan="1">1242</td><td align="center" valign="top" rowspan="1" colspan="1">44.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bone &amp; visceral</td><td align="center" valign="top" rowspan="1" colspan="1">195</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td><td align="center" valign="top" rowspan="1" colspan="1">134</td><td align="center" valign="top" rowspan="1" colspan="1">3.3</td><td align="center" valign="top" rowspan="1" colspan="1">61</td><td align="center" valign="top" rowspan="1" colspan="1">2.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Visceral only</td><td align="center" valign="top" rowspan="1" colspan="1">298</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td><td align="center" valign="top" rowspan="1" colspan="1">94</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">204</td><td align="center" valign="top" rowspan="1" colspan="1">7.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lymph node only</td><td align="center" valign="top" rowspan="1" colspan="1">1052</td><td align="center" valign="top" rowspan="1" colspan="1">15.4</td><td align="center" valign="top" rowspan="1" colspan="1">336</td><td align="center" valign="top" rowspan="1" colspan="1">8.3</td><td align="center" valign="top" rowspan="1" colspan="1">716</td><td align="center" valign="top" rowspan="1" colspan="1">25.5</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">2336</td><td align="center" valign="top" rowspan="1" colspan="1">34.1</td><td align="center" valign="top" rowspan="1" colspan="1">1751</td><td align="center" valign="top" rowspan="1" colspan="1">43.3</td><td align="center" valign="top" rowspan="1" colspan="1">585</td><td align="center" valign="top" rowspan="1" colspan="1">20.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Claim&#8208;based frailty index (CFI)</td><td align="center" valign="top" rowspan="1" colspan="1">0.2 (0.06)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (0.12&#8211;0.19)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16 (0.06)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (0.11&#8211;0.19)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16 (0.06)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (0.12&#8211;0.19)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CFI &lt;&#8201;0.25</td><td align="center" valign="top" rowspan="1" colspan="1">6211</td><td align="center" valign="top" rowspan="1" colspan="1">90.7</td><td align="center" valign="top" rowspan="1" colspan="1">3675</td><td align="center" valign="top" rowspan="1" colspan="1">90.9</td><td align="center" valign="top" rowspan="1" colspan="1">2536</td><td align="center" valign="top" rowspan="1" colspan="1">90.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CFI&#8201;&#8805;&#8201;0.25</td><td align="center" valign="top" rowspan="1" colspan="1">639</td><td align="center" valign="top" rowspan="1" colspan="1">9.3</td><td align="center" valign="top" rowspan="1" colspan="1">367</td><td align="center" valign="top" rowspan="1" colspan="1">9.1</td><td align="center" valign="top" rowspan="1" colspan="1">272</td><td align="center" valign="top" rowspan="1" colspan="1">9.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic conditions</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">5260</td><td align="center" valign="top" rowspan="1" colspan="1">76.8</td><td align="center" valign="top" rowspan="1" colspan="1">3064</td><td align="center" valign="top" rowspan="1" colspan="1">75.8</td><td align="center" valign="top" rowspan="1" colspan="1">2196</td><td align="center" valign="top" rowspan="1" colspan="1">78.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High cholesterol</td><td align="center" valign="top" rowspan="1" colspan="1">4884</td><td align="center" valign="top" rowspan="1" colspan="1">71.3</td><td align="center" valign="top" rowspan="1" colspan="1">2763</td><td align="center" valign="top" rowspan="1" colspan="1">68.4</td><td align="center" valign="top" rowspan="1" colspan="1">2121</td><td align="center" valign="top" rowspan="1" colspan="1">75.5</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Arthritis</td><td align="center" valign="top" rowspan="1" colspan="1">3340</td><td align="center" valign="top" rowspan="1" colspan="1">48.8</td><td align="center" valign="top" rowspan="1" colspan="1">1922</td><td align="center" valign="top" rowspan="1" colspan="1">47.6</td><td align="center" valign="top" rowspan="1" colspan="1">1418</td><td align="center" valign="top" rowspan="1" colspan="1">50.5</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Heart disease</td><td align="center" valign="top" rowspan="1" colspan="1">2499</td><td align="center" valign="top" rowspan="1" colspan="1">36.5</td><td align="center" valign="top" rowspan="1" colspan="1">1483</td><td align="center" valign="top" rowspan="1" colspan="1">36.7</td><td align="center" valign="top" rowspan="1" colspan="1">1016</td><td align="center" valign="top" rowspan="1" colspan="1">36.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Coronary artery disease</td><td align="center" valign="top" rowspan="1" colspan="1">2459</td><td align="center" valign="top" rowspan="1" colspan="1">35.9</td><td align="center" valign="top" rowspan="1" colspan="1">1441</td><td align="center" valign="top" rowspan="1" colspan="1">35.7</td><td align="center" valign="top" rowspan="1" colspan="1">1018</td><td align="center" valign="top" rowspan="1" colspan="1">36.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="top" rowspan="1" colspan="1">2315</td><td align="center" valign="top" rowspan="1" colspan="1">33.8</td><td align="center" valign="top" rowspan="1" colspan="1">1319</td><td align="center" valign="top" rowspan="1" colspan="1">32.6</td><td align="center" valign="top" rowspan="1" colspan="1">996</td><td align="center" valign="top" rowspan="1" colspan="1">35.5</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Osteoarthritis</td><td align="center" valign="top" rowspan="1" colspan="1">2013</td><td align="center" valign="top" rowspan="1" colspan="1">29.4</td><td align="center" valign="top" rowspan="1" colspan="1">1146</td><td align="center" valign="top" rowspan="1" colspan="1">28.4</td><td align="center" valign="top" rowspan="1" colspan="1">867</td><td align="center" valign="top" rowspan="1" colspan="1">30.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cardiac arrhythmia</td><td align="center" valign="top" rowspan="1" colspan="1">1855</td><td align="center" valign="top" rowspan="1" colspan="1">27.1</td><td align="center" valign="top" rowspan="1" colspan="1">1107</td><td align="center" valign="top" rowspan="1" colspan="1">27.4</td><td align="center" valign="top" rowspan="1" colspan="1">748</td><td align="center" valign="top" rowspan="1" colspan="1">26.6</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" valign="top" rowspan="1" colspan="1">1390</td><td align="center" valign="top" rowspan="1" colspan="1">20.3</td><td align="center" valign="top" rowspan="1" colspan="1">792</td><td align="center" valign="top" rowspan="1" colspan="1">19.6</td><td align="center" valign="top" rowspan="1" colspan="1">598</td><td align="center" valign="top" rowspan="1" colspan="1">21.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Thyroid</td><td align="center" valign="top" rowspan="1" colspan="1">1249</td><td align="center" valign="top" rowspan="1" colspan="1">18.2</td><td align="center" valign="top" rowspan="1" colspan="1">710</td><td align="center" valign="top" rowspan="1" colspan="1">17.6</td><td align="center" valign="top" rowspan="1" colspan="1">539</td><td align="center" valign="top" rowspan="1" colspan="1">19.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic kidney disease</td><td align="center" valign="top" rowspan="1" colspan="1">1249</td><td align="center" valign="top" rowspan="1" colspan="1">18.2</td><td align="center" valign="top" rowspan="1" colspan="1">786</td><td align="center" valign="top" rowspan="1" colspan="1">19.4</td><td align="center" valign="top" rowspan="1" colspan="1">463</td><td align="center" valign="top" rowspan="1" colspan="1">16.5</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Congestive heart failure</td><td align="center" valign="top" rowspan="1" colspan="1">1101</td><td align="center" valign="top" rowspan="1" colspan="1">16.1</td><td align="center" valign="top" rowspan="1" colspan="1">701</td><td align="center" valign="top" rowspan="1" colspan="1">17.3</td><td align="center" valign="top" rowspan="1" colspan="1">400</td><td align="center" valign="top" rowspan="1" colspan="1">14.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Anxiety</td><td align="center" valign="top" rowspan="1" colspan="1">675</td><td align="center" valign="top" rowspan="1" colspan="1">9.9</td><td align="center" valign="top" rowspan="1" colspan="1">382</td><td align="center" valign="top" rowspan="1" colspan="1">9.5</td><td align="center" valign="top" rowspan="1" colspan="1">293</td><td align="center" valign="top" rowspan="1" colspan="1">10.4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Depression</td><td align="center" valign="top" rowspan="1" colspan="1">671</td><td align="center" valign="top" rowspan="1" colspan="1">9.8</td><td align="center" valign="top" rowspan="1" colspan="1">397</td><td align="center" valign="top" rowspan="1" colspan="1">9.8</td><td align="center" valign="top" rowspan="1" colspan="1">274</td><td align="center" valign="top" rowspan="1" colspan="1">9.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gout</td><td align="center" valign="top" rowspan="1" colspan="1">602</td><td align="center" valign="top" rowspan="1" colspan="1">8.8</td><td align="center" valign="top" rowspan="1" colspan="1">362</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">240</td><td align="center" valign="top" rowspan="1" colspan="1">8.5</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Asthma</td><td align="center" valign="top" rowspan="1" colspan="1">473</td><td align="center" valign="top" rowspan="1" colspan="1">6.9</td><td align="center" valign="top" rowspan="1" colspan="1">260</td><td align="center" valign="top" rowspan="1" colspan="1">6.4</td><td align="center" valign="top" rowspan="1" colspan="1">213</td><td align="center" valign="top" rowspan="1" colspan="1">7.6</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Stroke</td><td align="center" valign="top" rowspan="1" colspan="1">323</td><td align="center" valign="top" rowspan="1" colspan="1">4.7</td><td align="center" valign="top" rowspan="1" colspan="1">192</td><td align="center" valign="top" rowspan="1" colspan="1">4.8</td><td align="center" valign="top" rowspan="1" colspan="1">131</td><td align="center" valign="top" rowspan="1" colspan="1">4.7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Osteoporosis</td><td align="center" valign="top" rowspan="1" colspan="1">274</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">138</td><td align="center" valign="top" rowspan="1" colspan="1">3.4</td><td align="center" valign="top" rowspan="1" colspan="1">136</td><td align="center" valign="top" rowspan="1" colspan="1">4.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">HIV</td><td align="center" valign="top" rowspan="1" colspan="1">199</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td><td align="center" valign="top" rowspan="1" colspan="1">114</td><td align="center" valign="top" rowspan="1" colspan="1">2.8</td><td align="center" valign="top" rowspan="1" colspan="1">85</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Rheumatoid arthritis</td><td align="center" valign="top" rowspan="1" colspan="1">169</td><td align="center" valign="top" rowspan="1" colspan="1">2.5</td><td align="center" valign="top" rowspan="1" colspan="1">93</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">76</td><td align="center" valign="top" rowspan="1" colspan="1">2.7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hepatitis</td><td align="center" valign="top" rowspan="1" colspan="1">167</td><td align="center" valign="top" rowspan="1" colspan="1">2.4</td><td align="center" valign="top" rowspan="1" colspan="1">100</td><td align="center" valign="top" rowspan="1" colspan="1">2.5</td><td align="center" valign="top" rowspan="1" colspan="1">67</td><td align="center" valign="top" rowspan="1" colspan="1">2.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Multimorbidity, by number of conditions</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hi Multimorbidity (7 or more)</td><td align="center" valign="top" rowspan="1" colspan="1">1567</td><td align="center" valign="top" rowspan="1" colspan="1">22.9</td><td align="center" valign="top" rowspan="1" colspan="1">933</td><td align="center" valign="top" rowspan="1" colspan="1">23.1</td><td align="center" valign="top" rowspan="1" colspan="1">634</td><td align="center" valign="top" rowspan="1" colspan="1">22.6</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Moderate Multimorbidity (3&#8211;6)</td><td align="center" valign="top" rowspan="1" colspan="1">3646</td><td align="center" valign="top" rowspan="1" colspan="1">53.2</td><td align="center" valign="top" rowspan="1" colspan="1">2070</td><td align="center" valign="top" rowspan="1" colspan="1">51.2</td><td align="center" valign="top" rowspan="1" colspan="1">1576</td><td align="center" valign="top" rowspan="1" colspan="1">56.1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No Multimorbidity (0&#8211;2)</td><td align="center" valign="top" rowspan="1" colspan="1">1637</td><td align="center" valign="top" rowspan="1" colspan="1">23.9</td><td align="center" valign="top" rowspan="1" colspan="1">1039</td><td align="center" valign="top" rowspan="1" colspan="1">25.7</td><td align="center" valign="top" rowspan="1" colspan="1">598</td><td align="center" valign="top" rowspan="1" colspan="1">21.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bone health agents&#8212;baseline</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Any bone health agents</td><td align="center" valign="top" rowspan="1" colspan="1">130</td><td align="center" valign="top" rowspan="1" colspan="1">1.9</td><td align="center" valign="top" rowspan="1" colspan="1">69</td><td align="center" valign="top" rowspan="1" colspan="1">1.7</td><td align="center" valign="top" rowspan="1" colspan="1">61</td><td align="center" valign="top" rowspan="1" colspan="1">2.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Denosumab</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Alendronate</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">0.8</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline healthcare resource use</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IP use</td><td align="center" valign="top" rowspan="1" colspan="1">1289</td><td align="center" valign="top" rowspan="1" colspan="1">18.8</td><td align="center" valign="top" rowspan="1" colspan="1">758</td><td align="center" valign="top" rowspan="1" colspan="1">18.8</td><td align="center" valign="top" rowspan="1" colspan="1">531</td><td align="center" valign="top" rowspan="1" colspan="1">18.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ER use</td><td align="center" valign="top" rowspan="1" colspan="1">2567</td><td align="center" valign="top" rowspan="1" colspan="1">37.5</td><td align="center" valign="top" rowspan="1" colspan="1">1605</td><td align="center" valign="top" rowspan="1" colspan="1">39.7</td><td align="center" valign="top" rowspan="1" colspan="1">962</td><td align="center" valign="top" rowspan="1" colspan="1">34.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diagnostic radiologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">5044</td><td align="center" valign="top" rowspan="1" colspan="1">73.6</td><td align="center" valign="top" rowspan="1" colspan="1">2772</td><td align="center" valign="top" rowspan="1" colspan="1">68.6</td><td align="center" valign="top" rowspan="1" colspan="1">2272</td><td align="center" valign="top" rowspan="1" colspan="1">80.9</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Urologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">4439</td><td align="center" valign="top" rowspan="1" colspan="1">64.8</td><td align="center" valign="top" rowspan="1" colspan="1">2384</td><td align="center" valign="top" rowspan="1" colspan="1">59</td><td align="center" valign="top" rowspan="1" colspan="1">2055</td><td align="center" valign="top" rowspan="1" colspan="1">73.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Oncologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">1492</td><td align="center" valign="top" rowspan="1" colspan="1">21.8</td><td align="center" valign="top" rowspan="1" colspan="1">363</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">1129</td><td align="center" valign="top" rowspan="1" colspan="1">40.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other specialist visit</td><td align="center" valign="top" rowspan="1" colspan="1">4917</td><td align="center" valign="top" rowspan="1" colspan="1">71.8</td><td align="center" valign="top" rowspan="1" colspan="1">2804</td><td align="center" valign="top" rowspan="1" colspan="1">69.4</td><td align="center" valign="top" rowspan="1" colspan="1">2113</td><td align="center" valign="top" rowspan="1" colspan="1">75.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PCP visit</td><td align="center" valign="top" rowspan="1" colspan="1">6138</td><td align="center" valign="top" rowspan="1" colspan="1">89.6</td><td align="center" valign="top" rowspan="1" colspan="1">3562</td><td align="center" valign="top" rowspan="1" colspan="1">88.1</td><td align="center" valign="top" rowspan="1" colspan="1">2576</td><td align="center" valign="top" rowspan="1" colspan="1">91.7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pain specialist visit</td><td align="center" valign="top" rowspan="1" colspan="1">1897</td><td align="center" valign="top" rowspan="1" colspan="1">27.7</td><td align="center" valign="top" rowspan="1" colspan="1">988</td><td align="center" valign="top" rowspan="1" colspan="1">24.4</td><td align="center" valign="top" rowspan="1" colspan="1">909</td><td align="center" valign="top" rowspan="1" colspan="1">32.4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Psychologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">327</td><td align="center" valign="top" rowspan="1" colspan="1">4.8</td><td align="center" valign="top" rowspan="1" colspan="1">194</td><td align="center" valign="top" rowspan="1" colspan="1">4.8</td><td align="center" valign="top" rowspan="1" colspan="1">133</td><td align="center" valign="top" rowspan="1" colspan="1">4.7</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Rheumatologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">225</td><td align="center" valign="top" rowspan="1" colspan="1">3.3</td><td align="center" valign="top" rowspan="1" colspan="1">117</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td><td align="center" valign="top" rowspan="1" colspan="1">108</td><td align="center" valign="top" rowspan="1" colspan="1">3.8</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ortho surgeon visit</td><td align="center" valign="top" rowspan="1" colspan="1">1240</td><td align="center" valign="top" rowspan="1" colspan="1">18.1</td><td align="center" valign="top" rowspan="1" colspan="1">701</td><td align="center" valign="top" rowspan="1" colspan="1">17.3</td><td align="center" valign="top" rowspan="1" colspan="1">539</td><td align="center" valign="top" rowspan="1" colspan="1">19.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gastroenterologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">1246</td><td align="center" valign="top" rowspan="1" colspan="1">18.2</td><td align="center" valign="top" rowspan="1" colspan="1">624</td><td align="center" valign="top" rowspan="1" colspan="1">15.4</td><td align="center" valign="top" rowspan="1" colspan="1">622</td><td align="center" valign="top" rowspan="1" colspan="1">22.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Anesthesiologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">1828</td><td align="center" valign="top" rowspan="1" colspan="1">26.7</td><td align="center" valign="top" rowspan="1" colspan="1">947</td><td align="center" valign="top" rowspan="1" colspan="1">23.4</td><td align="center" valign="top" rowspan="1" colspan="1">881</td><td align="center" valign="top" rowspan="1" colspan="1">31.4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Polypharmacy</td><td align="center" valign="top" rowspan="1" colspan="1">3140</td><td align="center" valign="top" rowspan="1" colspan="1">45.8</td><td align="center" valign="top" rowspan="1" colspan="1">1928</td><td align="center" valign="top" rowspan="1" colspan="1">47.7</td><td align="center" valign="top" rowspan="1" colspan="1">1212</td><td align="center" valign="top" rowspan="1" colspan="1">43.2</td></tr></tbody></table><table-wrap-foot id="cam471176-ntgp-0002"><fn id="cam471176-note-0002"><label>
<sup>a</sup>
</label><p>Missing values in marital status were randomly imputed.</p></fn><fn id="cam471176-note-0003"><label>
<sup>b</sup>
</label><p>Other: metastasis recorded in SEER without a corresponding claim indicating a specific site or had claim&#8208;based metastasis sites that did not fall into the predefined categories of bone, visceral, or lymph node metastases.</p></fn><fn id="cam471176-note-0004"><label>
<sup>c</sup>
</label><p>High risk was defined as Gleason score &#8805;&#8201;8, or PSA&#8201;&gt;&#8201;20 at PC diagnosis.</p></fn></table-wrap-foot></table-wrap><p>The majority (<italic toggle="yes">N</italic>&#8201;=&#8201;4042, 59.0%) had de novo metastases; among those who had recurrent metastases, the median time from PC diagnosis to metastasis was 48.0&#8201;months (IQR 9.0&#8211;86.1). Among the study cohort, 43.3% had bone metastasis only, 2.8% and 4.4% had visceral metastasis with and without bone metastasis, and 15.4% had lymph node metastasis only.</p></sec><sec id="cam471176-sec-0017"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">mHSPC</styled-content> Treatment Pattern</title><p>Among 6850 men in our study cohort, 2081 (30.4%) received no systemic treatment within 6 months of mHSPC diagnosis; 3225 (47.1%) received ADT monotherapy; 1017 (14.8%) received ADT plus ARPI, and 403 (5.9%) received ADT plus docetaxel; &lt;&#8201;2% received triplet therapy or other treatment combinations (Figure&#160;<xref rid="cam471176-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="cam471176-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Percent treated with ADT only, ADT&#8201;+&#8201;ARPI, and ADT&#8201;+&#8201;docetaxel among men aged 67 or older, and diagnosed with mHSPC between July 2016 and December 2019 (Total <italic toggle="yes">N</italic>&#8201;=&#8201;6850).</p></caption><graphic position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CAM4-14-e71176-g003.jpg"/></fig><p>Among 4645 men treated with ADT, the use of ADT&#8201;+&#8201;ARPI increased from 19.0% to 30.0% from 2017 to 2019, while treatments with ADT alone decreased from 72.1% to 62.6% and ADT plus docetaxel decreased from 8.8% to 7.3% (Figure&#160;<xref rid="cam471176-fig-0002" ref-type="fig">2</xref>). Notably, disparities were observed based on race and socioeconomic factors. Among non&#8208;Hispanic whites, 22.5% received ADT plus ARPI compared to 15.5% among non&#8208;Hispanic blacks (Table&#160;<xref rid="cam471176-tbl-0002" ref-type="table">2</xref>). Furthermore, individuals in the highest Yost Index quintile had higher rates of ADT plus ARPI (26.0%) and ADT plus docetaxel (9.2%) than those in the lowest quintile (15.1% and 6.3%, respectively).</p><fig position="float" fig-type="FIGURE" id="cam471176-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Trends in mHSPC treatment pattern in men aged 67 or older, diagnosed with mHSPC in 2016&#8211;2019, and treated with ADT (total <italic toggle="yes">N</italic>&#8201;=&#8201;4645). 2016 year includes only patients who started treatment on or after July 1, 2016. Triplet therapy was excluded due to the small number of individuals receiving treatment. ADT, androgen deprivation therapy; ARPI, androgen receptor pathway inhibitor; mHSPC, metastatic hormone&#8208;sensitive prostate cancer.</p></caption><graphic position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CAM4-14-e71176-g001.jpg"/></fig><table-wrap position="float" id="cam471176-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Baseline characteristics of individuals with mHSPC and treated with ADT by treatment.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Characteristics</th><th align="center" colspan="2" valign="bottom" rowspan="1">ADT</th><th align="center" colspan="2" valign="bottom" rowspan="1">ADT+ Docetaxel</th><th align="center" colspan="2" valign="bottom" rowspan="1">ADT&#8201;+&#8201;ARPI</th><th align="center" rowspan="2" valign="bottom" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>/mean (SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Row %/median (IQR)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>/mean (SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Row %/median (IQR)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>/mean (SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Row %/median (IQR)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Cohort size</td><td align="center" valign="top" rowspan="1" colspan="1">3225</td><td align="center" valign="top" rowspan="1" colspan="1">69.4</td><td align="center" valign="top" rowspan="1" colspan="1">403</td><td align="center" valign="top" rowspan="1" colspan="1">8.7</td><td align="center" valign="top" rowspan="1" colspan="1">1017</td><td align="center" valign="top" rowspan="1" colspan="1">21.9</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PC to mHSPC diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">15.78 (31.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0&#8211;5.95)</td><td align="center" valign="top" rowspan="1" colspan="1">10.16 (27.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0&#8211;0)</td><td align="center" valign="top" rowspan="1" colspan="1">14.5 (31.26)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0&#8211;2.01)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">mHSPC to ADT initiation</td><td align="center" valign="top" rowspan="1" colspan="1">1.69 (1.24)</td><td align="center" valign="top" rowspan="1" colspan="1">1.35 (0.82&#8211;2.24)</td><td align="center" valign="top" rowspan="1" colspan="1">1.42 (0.95)</td><td align="center" valign="top" rowspan="1" colspan="1">1.22 (0.79&#8211;1.74)</td><td align="center" valign="top" rowspan="1" colspan="1">1.44 (1.01)</td><td align="center" valign="top" rowspan="1" colspan="1">1.22 (0.76&#8211;1.87)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ADT use to ADT Intensification</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">1.31 (1.37)</td><td align="center" valign="top" rowspan="1" colspan="1">1.08 (0.43&#8211;2.01)</td><td align="center" valign="top" rowspan="1" colspan="1">1.23 (1.36)</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (0.2&#8211;1.91)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at mHSPC diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">77.7 (7.09)</td><td align="center" valign="top" rowspan="1" colspan="1">77 (72&#8211;83)</td><td align="center" valign="top" rowspan="1" colspan="1">72.93 (4.65)</td><td align="center" valign="top" rowspan="1" colspan="1">72 (69&#8211;76)</td><td align="center" valign="top" rowspan="1" colspan="1">76.35 (6.13)</td><td align="center" valign="top" rowspan="1" colspan="1">76 (71&#8211;81)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race and ethnicity</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NHW</td><td align="center" valign="top" rowspan="1" colspan="1">2527</td><td align="center" valign="top" rowspan="1" colspan="1">68.6</td><td align="center" valign="top" rowspan="1" colspan="1">325</td><td align="center" valign="top" rowspan="1" colspan="1">8.8</td><td align="center" valign="top" rowspan="1" colspan="1">830</td><td align="center" valign="top" rowspan="1" colspan="1">22.5</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NHB</td><td align="center" valign="top" rowspan="1" colspan="1">257</td><td align="center" valign="top" rowspan="1" colspan="1">78.1</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">6.4</td><td align="center" valign="top" rowspan="1" colspan="1">51</td><td align="center" valign="top" rowspan="1" colspan="1">15.5</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">219</td><td align="center" valign="top" rowspan="1" colspan="1">73.2</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">7.7</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">19.1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other/unknown</td><td align="center" valign="top" rowspan="1" colspan="1">222</td><td align="center" valign="top" rowspan="1" colspan="1">66.3</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">10.1</td><td align="center" valign="top" rowspan="1" colspan="1">79</td><td align="center" valign="top" rowspan="1" colspan="1">23.6</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marital status at PC diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Married</td><td align="center" valign="top" rowspan="1" colspan="1">1700</td><td align="center" valign="top" rowspan="1" colspan="1">67.0</td><td align="center" valign="top" rowspan="1" colspan="1">243</td><td align="center" valign="top" rowspan="1" colspan="1">9.6</td><td align="center" valign="top" rowspan="1" colspan="1">593</td><td align="center" valign="top" rowspan="1" colspan="1">23.4</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Widowed/divorced/separated</td><td align="center" valign="top" rowspan="1" colspan="1">1085</td><td align="center" valign="top" rowspan="1" colspan="1">72.9</td><td align="center" valign="top" rowspan="1" colspan="1">119</td><td align="center" valign="top" rowspan="1" colspan="1">8.0</td><td align="center" valign="top" rowspan="1" colspan="1">285</td><td align="center" valign="top" rowspan="1" colspan="1">19.1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Never married</td><td align="center" valign="top" rowspan="1" colspan="1">440</td><td align="center" valign="top" rowspan="1" colspan="1">71.0</td><td align="center" valign="top" rowspan="1" colspan="1">41</td><td align="center" valign="top" rowspan="1" colspan="1">6.6</td><td align="center" valign="top" rowspan="1" colspan="1">139</td><td align="center" valign="top" rowspan="1" colspan="1">22.4</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Region</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Northeast</td><td align="center" valign="top" rowspan="1" colspan="1">1115</td><td align="center" valign="top" rowspan="1" colspan="1">68.8</td><td align="center" valign="top" rowspan="1" colspan="1">122</td><td align="center" valign="top" rowspan="1" colspan="1">7.5</td><td align="center" valign="top" rowspan="1" colspan="1">384</td><td align="center" valign="top" rowspan="1" colspan="1">23.7</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">South</td><td align="center" valign="top" rowspan="1" colspan="1">842</td><td align="center" valign="top" rowspan="1" colspan="1">71.1</td><td align="center" valign="top" rowspan="1" colspan="1">116</td><td align="center" valign="top" rowspan="1" colspan="1">9.8</td><td align="center" valign="top" rowspan="1" colspan="1">226</td><td align="center" valign="top" rowspan="1" colspan="1">19.1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Midwest</td><td align="center" valign="top" rowspan="1" colspan="1">255</td><td align="center" valign="top" rowspan="1" colspan="1">71.8</td><td align="center" valign="top" rowspan="1" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1">12.1</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">16.1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">West</td><td align="center" valign="top" rowspan="1" colspan="1">1013</td><td align="center" valign="top" rowspan="1" colspan="1">68.2</td><td align="center" valign="top" rowspan="1" colspan="1">122</td><td align="center" valign="top" rowspan="1" colspan="1">8.2</td><td align="center" valign="top" rowspan="1" colspan="1">350</td><td align="center" valign="top" rowspan="1" colspan="1">23.6</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dual eligibility</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medicaid/medicare</td><td align="center" valign="top" rowspan="1" colspan="1">552</td><td align="center" valign="top" rowspan="1" colspan="1">75.2</td><td align="center" valign="top" rowspan="1" colspan="1">38</td><td align="center" valign="top" rowspan="1" colspan="1">5.2</td><td align="center" valign="top" rowspan="1" colspan="1">144</td><td align="center" valign="top" rowspan="1" colspan="1">19.6</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medicare only</td><td align="center" valign="top" rowspan="1" colspan="1">2673</td><td align="center" valign="top" rowspan="1" colspan="1">68.3</td><td align="center" valign="top" rowspan="1" colspan="1">365</td><td align="center" valign="top" rowspan="1" colspan="1">9.3</td><td align="center" valign="top" rowspan="1" colspan="1">873</td><td align="center" valign="top" rowspan="1" colspan="1">22.3</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">YOST quintile</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 1</td><td align="center" valign="top" rowspan="1" colspan="1">396</td><td align="center" valign="top" rowspan="1" colspan="1">78.6</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">6.3</td><td align="center" valign="top" rowspan="1" colspan="1">76</td><td align="center" valign="top" rowspan="1" colspan="1">15.1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 2</td><td align="center" valign="top" rowspan="1" colspan="1">473</td><td align="center" valign="top" rowspan="1" colspan="1">71.9</td><td align="center" valign="top" rowspan="1" colspan="1">66</td><td align="center" valign="top" rowspan="1" colspan="1">10.0</td><td align="center" valign="top" rowspan="1" colspan="1">119</td><td align="center" valign="top" rowspan="1" colspan="1">18.1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 3</td><td align="center" valign="top" rowspan="1" colspan="1">571</td><td align="center" valign="top" rowspan="1" colspan="1">71.3</td><td align="center" valign="top" rowspan="1" colspan="1">65</td><td align="center" valign="top" rowspan="1" colspan="1">8.1</td><td align="center" valign="top" rowspan="1" colspan="1">165</td><td align="center" valign="top" rowspan="1" colspan="1">20.6</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 4</td><td align="center" valign="top" rowspan="1" colspan="1">720</td><td align="center" valign="top" rowspan="1" colspan="1">69.4</td><td align="center" valign="top" rowspan="1" colspan="1">85</td><td align="center" valign="top" rowspan="1" colspan="1">8.2</td><td align="center" valign="top" rowspan="1" colspan="1">232</td><td align="center" valign="top" rowspan="1" colspan="1">22.4</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 5</td><td align="center" valign="top" rowspan="1" colspan="1">986</td><td align="center" valign="top" rowspan="1" colspan="1">64.8</td><td align="center" valign="top" rowspan="1" colspan="1">140</td><td align="center" valign="top" rowspan="1" colspan="1">9.2</td><td align="center" valign="top" rowspan="1" colspan="1">395</td><td align="center" valign="top" rowspan="1" colspan="1">26.0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PSA level at diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">43.6 (38.92)</td><td align="center" valign="top" rowspan="1" colspan="1">23.7 (8.8&#8211;98)</td><td align="center" valign="top" rowspan="1" colspan="1">57.59 (40.51)</td><td align="center" valign="top" rowspan="1" colspan="1">66.8 (12.7&#8211;98)</td><td align="center" valign="top" rowspan="1" colspan="1">52.61 (39.95)</td><td align="center" valign="top" rowspan="1" colspan="1">45.25 (11&#8211;98)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gleason score at diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">8.16 (1.06)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (7&#8211;9)</td><td align="center" valign="top" rowspan="1" colspan="1">8.59 (0.94)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (8&#8211;9)</td><td align="center" valign="top" rowspan="1" colspan="1">8.45 (1.04)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (8&#8211;9)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Risk group based on Gleason score and PSA values<xref rid="cam471176-note-0008" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">High risk</td><td align="center" valign="top" rowspan="1" colspan="1">617</td><td align="center" valign="top" rowspan="1" colspan="1">75.9</td><td align="center" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">5.4</td><td align="center" valign="top" rowspan="1" colspan="1">152</td><td align="center" valign="top" rowspan="1" colspan="1">18.7</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Not high risk</td><td align="center" valign="top" rowspan="1" colspan="1">1185</td><td align="center" valign="top" rowspan="1" colspan="1">65.4</td><td align="center" valign="top" rowspan="1" colspan="1">197</td><td align="center" valign="top" rowspan="1" colspan="1">10.9</td><td align="center" valign="top" rowspan="1" colspan="1">430</td><td align="center" valign="top" rowspan="1" colspan="1">23.7</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Multimorbidity, by number of conditions</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hi multimorbidity (7 or more)</td><td align="center" valign="top" rowspan="1" colspan="1">782</td><td align="center" valign="top" rowspan="1" colspan="1">76.2</td><td align="center" valign="top" rowspan="1" colspan="1">45</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td><td align="center" valign="top" rowspan="1" colspan="1">199</td><td align="center" valign="top" rowspan="1" colspan="1">19.4</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Moderate multimorbidity (3&#8211;6)</td><td align="center" valign="top" rowspan="1" colspan="1">1728</td><td align="center" valign="top" rowspan="1" colspan="1">69.4</td><td align="center" valign="top" rowspan="1" colspan="1">226</td><td align="center" valign="top" rowspan="1" colspan="1">9.1</td><td align="center" valign="top" rowspan="1" colspan="1">536</td><td align="center" valign="top" rowspan="1" colspan="1">21.5</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No multimorbidity (0&#8211;2)</td><td align="center" valign="top" rowspan="1" colspan="1">715</td><td align="center" valign="top" rowspan="1" colspan="1">63.3</td><td align="center" valign="top" rowspan="1" colspan="1">132</td><td align="center" valign="top" rowspan="1" colspan="1">11.7</td><td align="center" valign="top" rowspan="1" colspan="1">282</td><td align="center" valign="top" rowspan="1" colspan="1">25.0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline claim&#8208;based frailty index (CFI)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16 (0.06)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (0.12&#8211;0.19)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.04)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 (0.11&#8211;0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (0.05)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.11&#8211;0.17)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline Charlson comorbidity index</td><td align="center" valign="top" rowspan="1" colspan="1">2.05 (2.11)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0&#8211;3)</td><td align="center" valign="top" rowspan="1" colspan="1">1.26 (1.48)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0&#8211;2)</td><td align="center" valign="top" rowspan="1" colspan="1">1.73 (1.94)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0&#8211;3)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline care fragmentation index</td><td align="center" valign="top" rowspan="1" colspan="1">0.74 (0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.79 (0.70&#8211;0.85)</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (0.19)</td><td align="center" valign="top" rowspan="1" colspan="1">0.76 (0.64&#8211;0.84)</td><td align="center" valign="top" rowspan="1" colspan="1">0.74 (0.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.79 (0.68&#8211;0.85)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Claim&#8208;based spread of metastasis</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bone only</td><td align="center" valign="top" rowspan="1" colspan="1">1497</td><td align="center" valign="top" rowspan="1" colspan="1">66.9</td><td align="center" valign="top" rowspan="1" colspan="1">204</td><td align="center" valign="top" rowspan="1" colspan="1">9.1</td><td align="center" valign="top" rowspan="1" colspan="1">536</td><td align="center" valign="top" rowspan="1" colspan="1">24.0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bone and visceral</td><td align="center" valign="top" rowspan="1" colspan="1">83</td><td align="center" valign="top" rowspan="1" colspan="1">57.6</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">16.7</td><td align="center" valign="top" rowspan="1" colspan="1">37</td><td align="center" valign="top" rowspan="1" colspan="1">25.7</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Visceral only</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="center" valign="top" rowspan="1" colspan="1">63.2</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">14.9</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">21.9</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lymph node only</td><td align="center" valign="top" rowspan="1" colspan="1">521</td><td align="center" valign="top" rowspan="1" colspan="1">80.4</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td><td align="center" valign="top" rowspan="1" colspan="1">106</td><td align="center" valign="top" rowspan="1" colspan="1">16.4</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">1052</td><td align="center" valign="top" rowspan="1" colspan="1">70.0</td><td align="center" valign="top" rowspan="1" colspan="1">137</td><td align="center" valign="top" rowspan="1" colspan="1">9.1</td><td align="center" valign="top" rowspan="1" colspan="1">313</td><td align="center" valign="top" rowspan="1" colspan="1">20.8</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthcare resource use</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IP use<xref rid="cam471176-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">619</td><td align="center" valign="top" rowspan="1" colspan="1">74.8</td><td align="center" valign="top" rowspan="1" colspan="1">45</td><td align="center" valign="top" rowspan="1" colspan="1">5.4</td><td align="center" valign="top" rowspan="1" colspan="1">164</td><td align="center" valign="top" rowspan="1" colspan="1">19.8</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No IP use</td><td align="center" valign="top" rowspan="1" colspan="1">2606</td><td align="center" valign="top" rowspan="1" colspan="1">68.3</td><td align="center" valign="top" rowspan="1" colspan="1">358</td><td align="center" valign="top" rowspan="1" colspan="1">9.4</td><td align="center" valign="top" rowspan="1" colspan="1">853</td><td align="center" valign="top" rowspan="1" colspan="1">22.3</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ER use<xref rid="cam471176-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1268</td><td align="center" valign="top" rowspan="1" colspan="1">73.0</td><td align="center" valign="top" rowspan="1" colspan="1">120</td><td align="center" valign="top" rowspan="1" colspan="1">6.9</td><td align="center" valign="top" rowspan="1" colspan="1">348</td><td align="center" valign="top" rowspan="1" colspan="1">20.0</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No ER use</td><td align="center" valign="top" rowspan="1" colspan="1">1957</td><td align="center" valign="top" rowspan="1" colspan="1">67.3</td><td align="center" valign="top" rowspan="1" colspan="1">283</td><td align="center" valign="top" rowspan="1" colspan="1">9.7</td><td align="center" valign="top" rowspan="1" colspan="1">669</td><td align="center" valign="top" rowspan="1" colspan="1">23.0</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diagnostic radiologist visit<xref rid="cam471176-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2507</td><td align="center" valign="top" rowspan="1" colspan="1">66.7</td><td align="center" valign="top" rowspan="1" colspan="1">368</td><td align="center" valign="top" rowspan="1" colspan="1">9.8</td><td align="center" valign="top" rowspan="1" colspan="1">881</td><td align="center" valign="top" rowspan="1" colspan="1">23.5</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No diagnostic radiologist Visit</td><td align="center" valign="top" rowspan="1" colspan="1">718</td><td align="center" valign="top" rowspan="1" colspan="1">80.8</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">3.9</td><td align="center" valign="top" rowspan="1" colspan="1">136</td><td align="center" valign="top" rowspan="1" colspan="1">15.3</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Urologist visit<xref rid="cam471176-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2455</td><td align="center" valign="top" rowspan="1" colspan="1">69.7</td><td align="center" valign="top" rowspan="1" colspan="1">305</td><td align="center" valign="top" rowspan="1" colspan="1">8.7</td><td align="center" valign="top" rowspan="1" colspan="1">760</td><td align="center" valign="top" rowspan="1" colspan="1">21.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.663</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No urologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">770</td><td align="center" valign="top" rowspan="1" colspan="1">68.4</td><td align="center" valign="top" rowspan="1" colspan="1">98</td><td align="center" valign="top" rowspan="1" colspan="1">8.7</td><td align="center" valign="top" rowspan="1" colspan="1">257</td><td align="center" valign="top" rowspan="1" colspan="1">22.8</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Oncologist visit<xref rid="cam471176-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2206</td><td align="center" valign="top" rowspan="1" colspan="1">64.1</td><td align="center" valign="top" rowspan="1" colspan="1">367</td><td align="center" valign="top" rowspan="1" colspan="1">10.7</td><td align="center" valign="top" rowspan="1" colspan="1">868</td><td align="center" valign="top" rowspan="1" colspan="1">25.2</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No oncologist Visit</td><td align="center" valign="top" rowspan="1" colspan="1">1019</td><td align="center" valign="top" rowspan="1" colspan="1">84.6</td><td align="center" valign="top" rowspan="1" colspan="1">36</td><td align="center" valign="top" rowspan="1" colspan="1">3.0</td><td align="center" valign="top" rowspan="1" colspan="1">149</td><td align="center" valign="top" rowspan="1" colspan="1">12.4</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other specialist visit<xref rid="cam471176-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1438</td><td align="center" valign="top" rowspan="1" colspan="1">68.5</td><td align="center" valign="top" rowspan="1" colspan="1">189</td><td align="center" valign="top" rowspan="1" colspan="1">9.0</td><td align="center" valign="top" rowspan="1" colspan="1">471</td><td align="center" valign="top" rowspan="1" colspan="1">22.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.482</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No other specialist visit</td><td align="center" valign="top" rowspan="1" colspan="1">1787</td><td align="center" valign="top" rowspan="1" colspan="1">70.2</td><td align="center" valign="top" rowspan="1" colspan="1">214</td><td align="center" valign="top" rowspan="1" colspan="1">8.4</td><td align="center" valign="top" rowspan="1" colspan="1">546</td><td align="center" valign="top" rowspan="1" colspan="1">21.4</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthcare resource use</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PCP visit<xref rid="cam471176-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2200</td><td align="center" valign="top" rowspan="1" colspan="1">68.3</td><td align="center" valign="top" rowspan="1" colspan="1">289</td><td align="center" valign="top" rowspan="1" colspan="1">9.0</td><td align="center" valign="top" rowspan="1" colspan="1">730</td><td align="center" valign="top" rowspan="1" colspan="1">22.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No PCP visit</td><td align="center" valign="top" rowspan="1" colspan="1">1025</td><td align="center" valign="top" rowspan="1" colspan="1">71.9</td><td align="center" valign="top" rowspan="1" colspan="1">114</td><td align="center" valign="top" rowspan="1" colspan="1">8.0</td><td align="center" valign="top" rowspan="1" colspan="1">287</td><td align="center" valign="top" rowspan="1" colspan="1">20.1</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pain specialist visit<xref rid="cam471176-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">516</td><td align="center" valign="top" rowspan="1" colspan="1">64.2</td><td align="center" valign="top" rowspan="1" colspan="1">95</td><td align="center" valign="top" rowspan="1" colspan="1">11.8</td><td align="center" valign="top" rowspan="1" colspan="1">193</td><td align="center" valign="top" rowspan="1" colspan="1">24.0</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No pain specialist visit</td><td align="center" valign="top" rowspan="1" colspan="1">2709</td><td align="center" valign="top" rowspan="1" colspan="1">70.5</td><td align="center" valign="top" rowspan="1" colspan="1">308</td><td align="center" valign="top" rowspan="1" colspan="1">8.0</td><td align="center" valign="top" rowspan="1" colspan="1">824</td><td align="center" valign="top" rowspan="1" colspan="1">21.5</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ortho surgeon visit<xref rid="cam471176-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">202</td><td align="center" valign="top" rowspan="1" colspan="1">63.7</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">10.1</td><td align="center" valign="top" rowspan="1" colspan="1">83</td><td align="center" valign="top" rowspan="1" colspan="1">26.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.073</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No ortho surgeon visit</td><td align="center" valign="top" rowspan="1" colspan="1">3023</td><td align="center" valign="top" rowspan="1" colspan="1">69.8</td><td align="center" valign="top" rowspan="1" colspan="1">371</td><td align="center" valign="top" rowspan="1" colspan="1">8.6</td><td align="center" valign="top" rowspan="1" colspan="1">934</td><td align="center" valign="top" rowspan="1" colspan="1">21.6</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gastroenterologist visit<xref rid="cam471176-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">223</td><td align="center" valign="top" rowspan="1" colspan="1">62.6</td><td align="center" valign="top" rowspan="1" colspan="1">40</td><td align="center" valign="top" rowspan="1" colspan="1">11.2</td><td align="center" valign="top" rowspan="1" colspan="1">93</td><td align="center" valign="top" rowspan="1" colspan="1">26.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No gastroenterologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">3002</td><td align="center" valign="top" rowspan="1" colspan="1">70.0</td><td align="center" valign="top" rowspan="1" colspan="1">363</td><td align="center" valign="top" rowspan="1" colspan="1">8.5</td><td align="center" valign="top" rowspan="1" colspan="1">924</td><td align="center" valign="top" rowspan="1" colspan="1">21.5</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Anesthesiologist visit<xref rid="cam471176-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">491</td><td align="center" valign="top" rowspan="1" colspan="1">64.0</td><td align="center" valign="top" rowspan="1" colspan="1">92</td><td align="center" valign="top" rowspan="1" colspan="1">12.0</td><td align="center" valign="top" rowspan="1" colspan="1">184</td><td align="center" valign="top" rowspan="1" colspan="1">24.0</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No anesthesiologist visit</td><td align="center" valign="top" rowspan="1" colspan="1">2734</td><td align="center" valign="top" rowspan="1" colspan="1">70.5</td><td align="center" valign="top" rowspan="1" colspan="1">311</td><td align="center" valign="top" rowspan="1" colspan="1">8.0</td><td align="center" valign="top" rowspan="1" colspan="1">833</td><td align="center" valign="top" rowspan="1" colspan="1">21.5</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Polypharmacy (&#8805;&#8201;6 drugs)<xref rid="cam471176-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1538</td><td align="center" valign="top" rowspan="1" colspan="1">71.2</td><td align="center" valign="top" rowspan="1" colspan="1">158</td><td align="center" valign="top" rowspan="1" colspan="1">7.3</td><td align="center" valign="top" rowspan="1" colspan="1">464</td><td align="center" valign="top" rowspan="1" colspan="1">21.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No polypharmacy</td><td align="center" valign="top" rowspan="1" colspan="1">1687</td><td align="center" valign="top" rowspan="1" colspan="1">67.9</td><td align="center" valign="top" rowspan="1" colspan="1">245</td><td align="center" valign="top" rowspan="1" colspan="1">9.9</td><td align="center" valign="top" rowspan="1" colspan="1">553</td><td align="center" valign="top" rowspan="1" colspan="1">22.3</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cam471176-ntgp-0003"><fn id="cam471176-note-0005"><p>Abbreviations: ADT, androgen deprivation therapy; ARPI, androgen receptor pathway inhibitor; BHA, bone health agent; CCI, Charlson Comorbidity Index; CHF, congestive heart failure; CVD, cerebrovascular disease; IQR, interquartile range; MI, myocardial infarction; MMC, Medicaid Managed Care; PVD, peripheral vascular disease; SD, standard deviation.</p></fn><fn id="cam471176-note-0006"><label>
<sup>a</sup>
</label><p>Baseline IP use, ER use, Polypharmacy 12&#8201;months before mHSPC diagnosis.</p></fn><fn id="cam471176-note-0007"><label>
<sup>b</sup>
</label><p>Any visit within 30&#8201;days before and 30&#8201;days after ADT initiation. YOST index has missing data and will not add to total numbers (not presented).</p></fn><fn id="cam471176-note-0008"><label>
<sup>c</sup>
</label><p>High risk was defined as Gleason score &#8805;&#8201;8, or PSA&#8201;&gt;&#8201;20 at PC diagnosis.</p></fn></table-wrap-foot></table-wrap><p>Additionally, individuals with higher PC risk, indicated by PSA levels and Gleason scores, were less likely to receive ADT plus ARPI (18.7%) and ADT plus docetaxel (5.4%) compared to not high&#8208;risk individuals (23.7% and 10.9%, respectively). Those with bone and visceral metastases were more likely to receive ADT plus ARPI (25.7%) and ADT plus docetaxel (16.7%). Moreover, individuals with high multimorbidity exhibited lower rates of receiving ADT plus ARPI (19.4%) and ADT plus docetaxel (4.4%) compared to those without multimorbidity (25.0% and 11.7%). The mean Charlson comorbidity score was found to be lower among those receiving intensified ADT compared to those on ADT alone. Physician specialty of visits near the mHSPC diagnosis date (within 30&#8201;days before and 30&#8201;days after index date) was also associated with treatment category. Men who had oncologist visits had higher rates of receiving ADT&#8201;+&#8201;ARPI (25.2% vs. 12.4%) or ADT&#8201;+&#8201;docetaxel (10.7% vs. 3.0%) compared with those who had no oncologist visit; however, no difference was observed between men with and without urologist visits near mHSPC diagnosis.</p></sec><sec id="cam471176-sec-0018"><label>3.3</label><title>Baseline Characteristics Associated With <styled-content style="fixed-case" toggle="no">ADT</styled-content> Combined With <styled-content style="fixed-case" toggle="no">ARPI</styled-content> and/or Docetaxel</title><p>In multinomial logistic regression analysis (Table&#160;<xref rid="cam471176-tbl-0003" ref-type="table">3</xref>), patients diagnosed with de novo mHSPC exhibited a greater propensity to receive ADT in conjunction with docetaxel (adjusted odds ratio [aOR]&#8201;=&#8201;2.73, 95% confidence interval [CI]&#8201;=&#8201;[2.07, 3.60]) or ADT combined with ARPI (aOR&#8201;=&#8201;1.56, 95% CI&#8201;=&#8201;[1.32, 1.84]) compared to those receiving ADT alone. Conversely, non&#8208;Hispanic Black men demonstrated a decreased likelihood of receiving ADT combined with ARPI (aOR&#8201;=&#8201;0.71, 95% CI&#8201;=&#8201;[0.51, 0.98]). Moreover, dual eligible low&#8208;income patients exhibited a reduced likelihood of receiving ADT combined with docetaxel (aOR&#8201;=&#8201;0.59, 95% CI&#8201;=&#8201;[0.40, 0.87]). Socioeconomic status emerged as a significant factor, with individuals residing in the lowest socioeconomic quintile (YOST Quintile 1) demonstrating a diminished likelihood of receiving either ADT combined with docetaxel (aOR&#8201;=&#8201;0.62, 95% CI&#8201;=&#8201;[0.39, 0.97]) or ADT combined with ARPI (aOR&#8201;=&#8201;0.54, 95% CI&#8201;=&#8201;[0.40, 0.74]) relative to those in the highest quintile (YOST Quintile 5). Furthermore, higher frailty was correlated with a lower likelihood of receiving intensified therapies; specifically, one percentage point increase in frailty index is associated with a 7% and 3% decrease in the odds of receiving ADT combined with docetaxel (aOR&#8201;=&#8201;0.93, 95% CI&#8201;=&#8201;[0.91, 0.95]) and ADT combined with ARPI (aOR&#8201;=&#8201;0.97, 95% CI&#8201;=&#8201;[0.96, 0.98]), respectively. Age at diagnosis also influenced treatment modalities; patients aged 75&#8201;years and older were less likely to receive ADT combined with docetaxel (aOR&#8201;=&#8201;0.41, 95% CI&#8201;=&#8201;[0.32, 0.52]), while the likelihood of receiving ADT combined with ARPI did not show a statistically significant difference (aOR&#8201;=&#8201;0.97, 95% CI&#8201;=&#8201;[0.78, 1.20]).</p><table-wrap position="float" id="cam471176-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Adjusted odds ratios and 95% confidence intervals from multinomial logistic regressions: ADT&#8201;+&#8201;docetaxel, ADT&#8201;+&#8201;ARPI (reference group: ADT only).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Characteristics</th><th align="center" colspan="3" valign="bottom" rowspan="1">ADT&#8201;+&#8201;Docetaxel</th><th align="center" colspan="3" valign="bottom" rowspan="1">ADT&#8201;+&#8201;ARPI</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">aOR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">aOR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">mHSPC diagnosis year (continuous variable, 2016 is Year 0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">[0.79, 0.97]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0100</td><td align="center" valign="top" rowspan="1" colspan="1">1.64</td><td align="center" valign="top" rowspan="1" colspan="1">[1.52, 1.78]</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">De novo metastases (reference group: recurrent)</td><td align="center" valign="top" rowspan="1" colspan="1">2.73</td><td align="center" valign="top" rowspan="1" colspan="1">[2.07, 3.60]</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.56</td><td align="center" valign="top" rowspan="1" colspan="1">[1.32, 1.84]</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age&#8201;&#8805;&#8201;75&#8201;years at mHSPC diagnosis (reference group: age 67&#8211;74&#8201;years)</td><td align="center" valign="top" rowspan="1" colspan="1">0.41</td><td align="center" valign="top" rowspan="1" colspan="1">[0.32, 0.52]</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.97</td><td align="center" valign="top" rowspan="1" colspan="1">[0.78, 1.20]</td><td align="center" valign="top" rowspan="1" colspan="1">0.7700</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Race and ethnicity (reference group: NHW)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NHB</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td><td align="center" valign="top" rowspan="1" colspan="1">[0.42, 1.11]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1229</td><td align="center" valign="top" rowspan="1" colspan="1">0.71</td><td align="center" valign="top" rowspan="1" colspan="1">[0.51, 0.98]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0369</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="center" valign="top" rowspan="1" colspan="1">1.04</td><td align="center" valign="top" rowspan="1" colspan="1">[0.64, 1.68]</td><td align="center" valign="top" rowspan="1" colspan="1">0.8771</td><td align="center" valign="top" rowspan="1" colspan="1">0.89</td><td align="center" valign="top" rowspan="1" colspan="1">[0.64, 1.23]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4780</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other/unknown</td><td align="center" valign="top" rowspan="1" colspan="1">1.16</td><td align="center" valign="top" rowspan="1" colspan="1">[0.78, 1.74]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4674</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">[0.75, 1.32]</td><td align="center" valign="top" rowspan="1" colspan="1">0.9524</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Marital status at PC diagnosis (reference group: married)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Widowed/divorced/separated</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">[0.68, 1.11]</td><td align="center" valign="top" rowspan="1" colspan="1">0.2514</td><td align="center" valign="top" rowspan="1" colspan="1">0.76</td><td align="center" valign="top" rowspan="1" colspan="1">[0.64, 0.90]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0012</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Never married</td><td align="center" valign="top" rowspan="1" colspan="1">0.77</td><td align="center" valign="top" rowspan="1" colspan="1">[0.54, 1.10]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1512</td><td align="center" valign="top" rowspan="1" colspan="1">0.92</td><td align="center" valign="top" rowspan="1" colspan="1">[0.73, 1.14]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4394</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Region at PC diagnosis (reference group: northeast)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">South</td><td align="center" valign="top" rowspan="1" colspan="1">1.37</td><td align="center" valign="top" rowspan="1" colspan="1">[1.02, 1.85]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0362</td><td align="center" valign="top" rowspan="1" colspan="1">0.90</td><td align="center" valign="top" rowspan="1" colspan="1">[0.73, 1.11]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3181</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Midwest</td><td align="center" valign="top" rowspan="1" colspan="1">1.49</td><td align="center" valign="top" rowspan="1" colspan="1">[0.99, 2.22]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0547</td><td align="center" valign="top" rowspan="1" colspan="1">0.65</td><td align="center" valign="top" rowspan="1" colspan="1">[0.47, 0.90]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0100</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">West</td><td align="center" valign="top" rowspan="1" colspan="1">1.03</td><td align="center" valign="top" rowspan="1" colspan="1">[0.78, 1.37]</td><td align="center" valign="top" rowspan="1" colspan="1">0.8111</td><td align="center" valign="top" rowspan="1" colspan="1">0.98</td><td align="center" valign="top" rowspan="1" colspan="1">[0.82, 1.17]</td><td align="center" valign="top" rowspan="1" colspan="1">0.7931</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Urban (reference group: rural)</td><td align="center" valign="top" rowspan="1" colspan="1">1.35</td><td align="center" valign="top" rowspan="1" colspan="1">[0.56, 3.25]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4988</td><td align="center" valign="top" rowspan="1" colspan="1">1.22</td><td align="center" valign="top" rowspan="1" colspan="1">[0.64, 2.33]</td><td align="center" valign="top" rowspan="1" colspan="1">0.5444</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">YOST index quintile<xref rid="cam471176-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref> (reference group: Quintile 5)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 1</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td><td align="center" valign="top" rowspan="1" colspan="1">[0.39, 0.97]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0364</td><td align="center" valign="top" rowspan="1" colspan="1">0.54</td><td align="center" valign="top" rowspan="1" colspan="1">[0.40, 0.74]</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 2</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">[0.71, 1.40]</td><td align="center" valign="top" rowspan="1" colspan="1">0.9652</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td><td align="center" valign="top" rowspan="1" colspan="1">[0.53, 0.88]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0031</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 3</td><td align="center" valign="top" rowspan="1" colspan="1">0.78</td><td align="center" valign="top" rowspan="1" colspan="1">[0.56, 1.09]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1434</td><td align="center" valign="top" rowspan="1" colspan="1">0.77</td><td align="center" valign="top" rowspan="1" colspan="1">[0.61, 0.96]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0195</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Quintile 4</td><td align="center" valign="top" rowspan="1" colspan="1">0.82</td><td align="center" valign="top" rowspan="1" colspan="1">[0.61, 1.10]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1882</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td><td align="center" valign="top" rowspan="1" colspan="1">[0.68, 1.01]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0611</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dual eligibility in baseline period (medicare/medicaid) (reference group: medicare only)</td><td align="center" valign="top" rowspan="1" colspan="1">0.59</td><td align="center" valign="top" rowspan="1" colspan="1">[0.40, 0.87]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0072</td><td align="center" valign="top" rowspan="1" colspan="1">1.07</td><td align="center" valign="top" rowspan="1" colspan="1">[0.85, 1.35]</td><td align="center" valign="top" rowspan="1" colspan="1">0.5723</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Frailty index in baseline period<xref rid="cam471176-note-0010" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.93</td><td align="center" valign="top" rowspan="1" colspan="1">[0.91, 0.95]</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.97</td><td align="center" valign="top" rowspan="1" colspan="1">[0.96, 0.98]</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot id="cam471176-ntgp-0004"><fn id="cam471176-note-0009"><label>
<sup>a</sup>
</label><p>Missing indicator for YOST index included but not presented in the table.</p></fn><fn id="cam471176-note-0010"><label>
<sup>b</sup>
</label><p>Frailty index is expressed as a percentage.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cam471176-sec-0019"><label>3.4</label><title>Next Line of Treatment After Index Therapy</title><p>Among the 4645 individuals treated with ADT, 1526 (32.9%) initiated another systemic therapy during the follow&#8208;up period (Figure&#160;<xref rid="cam471176-fig-0003" ref-type="fig">3</xref>; Appendix&#160;<xref rid="cam471176-app-0003" ref-type="app">3</xref>). The most common subsequent treatment following the index therapy was ARPIs. Among the 3225 men initially treated with ADT monotherapy, 31.8% (<italic toggle="yes">N</italic>&#8201;=&#8201;1028) transitioned to another therapy, with abiraterone (<italic toggle="yes">N</italic>&#8201;=&#8201;469) and enzalutamide (<italic toggle="yes">N</italic>&#8201;=&#8201;434) being the most frequent next treatments (Figure&#160;<xref rid="cam471176-fig-0003" ref-type="fig">3</xref>; Appendix&#160;<xref rid="cam471176-app-0003" ref-type="app">3</xref>). By comparison, 27.6% (<italic toggle="yes">N</italic>&#8201;=&#8201;281) of men who began treatment with ADT combined with an ARPI initiated another therapy, most commonly transitioning from abiraterone to enzalutamide (<italic toggle="yes">N</italic>&#8201;=&#8201;161) or from abiraterone to docetaxel (<italic toggle="yes">N</italic>&#8201;=&#8201;66). For those initially treated with ADT combined with chemotherapy, more than half (53.8%, <italic toggle="yes">N</italic>&#8201;=&#8201;217) transitioned to another therapy, with abiraterone (<italic toggle="yes">N</italic>&#8201;=&#8201;143) and enzalutamide (<italic toggle="yes">N</italic>&#8201;=&#8201;68) being the most common choices (Figure&#160;<xref rid="cam471176-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="cam471176-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Flow of subsequent treatments after index therapy in patients treated with ADT among men aged 67 or older, diagnosed with mHSPC in 2016&#8211;2019, and treated with ADT. *Percentages were suppressed due to small cell sizes.</p></caption><graphic position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CAM4-14-e71176-g002.jpg"/></fig><p>The average time from ADT monotherapy initiation to the next treatment was 14.9&#8201;months for abiraterone and 15.5&#8201;months for enzalutamide (Appendix&#160;<xref rid="cam471176-app-0003" ref-type="app">3</xref>). For men who received initial treatment with docetaxel, the average time to subsequent therapy was 12.9&#8201;months for abiraterone and 16.9&#8201;months for enzalutamide. Among men initially treated with an ARPI, the average durations to abiraterone and enzalutamide were 11.2 and 11.5&#8201;months, respectively.</p></sec></sec><sec sec-type="discussion" id="cam471176-sec-0020"><label>4</label><title>Discussion</title><p>In this study, we analyzed initial treatment patterns among older men diagnosed with mHSPC in the US between 2016 and 2020. The nationwide cancer SEER registry data linked with Medicare claims data enabled us to examine a large number of cancer cases with detailed treatment information, ensuring high accuracy in both the identification of mHSPC cases and the tracking of treatment regimens. The linked dataset incorporates a comprehensive set of demographics, clinical, and SDoH factors among a diverse group of individuals, allowing for an in&#8208;depth exploration of treatment patterns and disparities.</p><p>ADT monotherapy was still prevalent, accounting for 67.6% of systemic mHSPC treatments over the study period. Single&#8208;modality treatment among older adults may reflect clinical considerations, such as contraindications to intensified therapy, concerns about adverse effects, limited survival benefits in patients with poor functional status or multiple comorbidities, and cost&#8208;related barriers [<xref rid="cam471176-bib-0021" ref-type="bibr">21</xref>]. Among men who received systemic treatment, intensification with docetaxel decreased from 14.5% to 8.8% during 2016&#8211;2017, and remained stable at 7.3% during 2018&#8211;2020. Conversely, ARPI treatment surged from 2.8% to 30.0% over the study period. Our findings align with other studies using Veterans Health Administration data&#160;[<xref rid="cam471176-bib-0018" ref-type="bibr">18</xref>], chart reviews [<xref rid="cam471176-bib-0022" ref-type="bibr">22</xref>], open claims&#160;[<xref rid="cam471176-bib-0019" ref-type="bibr">19</xref>], and clinical electronic health records [<xref rid="cam471176-bib-0023" ref-type="bibr">23</xref>]. These changes in treatment patterns were likely driven by approval and guideline updates recommending intensification and incorporating novel ARPIs. Despite a significant increase in the rate of intensified therapy, the high prevalence of ADT monotherapy underscores gaps in receiving approved and guideline&#8208;recommended treatment.</p><p>Aligning with existing studies [<xref rid="cam471176-bib-0024" ref-type="bibr">24</xref>], we found that men who were younger, had de novo mHSPC, higher PSA and Gleason scores at PC diagnosis, and had visceral metastases were more likely to receive treatment intensification. Additionally, treatment patterns varied by physician specialty, with oncologists, who often manage older, higher comorbidity patients, being more likely to prescribe combination therapies than urologists.</p><p>Our study expands previous literature by highlighting disparities in mHSPC treatment based on race and ethnicity, marital status, region, income, and neighborhood social&#8208;economic status as captured by the YOST index. Compared with Non&#8208;Hispanic White men, Non&#8208;Hispanic black men had lower odds of receiving intensified therapy with ARPI. In contrast, such disparities did not exist in other ethnic groups. Our findings in racial disparity align with recent studies [<xref rid="cam471176-bib-0018" ref-type="bibr">18</xref>, <xref rid="cam471176-bib-0023" ref-type="bibr">23</xref>, <xref rid="cam471176-bib-0025" ref-type="bibr">25</xref>]. Additionally, men residing in the Midwest and those who were widowed, divorced, or separated were less likely to receive ARPI, and dual eligible low&#8208;income individuals had reduced odds of receiving treatment intensification with docetaxel. A novel finding from our study was the gradient decrease in the odds of receiving ADT + ARPI from the top YOST Index Quintiles to the bottom, indicating neighborhood socioeconomic status remained an independent predictor of receiving novel therapy after adjusting for demographic, clinical, and other SDoH characteristics.</p><p>The observed disparities in mHSPC treatment may stem from systemic, neighborhood, and patient&#8208;level factors. NHB, unmarried, low&#8208;income individuals may face barriers such as high out&#8208;of&#8208;pocket costs for intensified therapies [<xref rid="cam471176-bib-0026" ref-type="bibr">26</xref>], restrictive formulary policies or delayed approval for treatment intensification [<xref rid="cam471176-bib-0027" ref-type="bibr">27</xref>], limited health literacy [<xref rid="cam471176-bib-0028" ref-type="bibr">28</xref>], and lack of caregiving support [<xref rid="cam471176-bib-0029" ref-type="bibr">29</xref>]. Furthermore, men living in neighborhoods with lower socioeconomic status may experience limited access to oncology specialists or comprehensive cancer centers [<xref rid="cam471176-bib-0030" ref-type="bibr">30</xref>]. These inequities are particularly concerning given that disadvantaged groups consistently experience poorer outcomes, such as earlier disease progression and worse OS [<xref rid="cam471176-bib-0031" ref-type="bibr">31</xref>, <xref rid="cam471176-bib-0032" ref-type="bibr">32</xref>].</p><p>Reducing disparities in treatment access is critical to narrowing survival gaps and improving health equity among older men with mHSPC. Ensuring equitable access to guideline&#8208;recommended therapies requires a multifaceted approach, including targeted patient outreach, policies aimed at improving care coordination, and programs designed to address patients' social needs. The Inflation Reduction Act offers a promising step toward mitigating financial toxicity associated with advanced cancer treatment by capping total out&#8208;of&#8208;pocket costs at $2000 [<xref rid="cam471176-bib-0033" ref-type="bibr">33</xref>]. Such measures are essential for advancing equity and improving outcomes for older adults with advanced PC.</p><p>A noteworthy finding is that nearly one&#8208;third of patients initially treated with ADT (whether as monotherapy or in combination) eventually received additional systemic treatment, with ARPIs emerging as the most common next line option. The average time from ADT to subsequent therapy varied by initial treatment category. Patients who were on ADT only experienced a longer duration before transition to the next line of therapy, suggesting a need to intensify therapy earlier and facilitate access to other lines of treatment. Variations in duration may also reflect differences in disease severity, response profile, or patient selection. These findings suggest the need for personalized treatment strategies based on individual risk profiles and the initial choice of therapy [<xref rid="cam471176-bib-0034" ref-type="bibr">34</xref>].</p></sec><sec id="cam471176-sec-0021"><label>5</label><title>Limitations</title><p>This study has several limitations that should be considered when interpreting the findings. First, due to a 3&#8208;year lag in data release from NCI and Medicare, our data may not fully capture the adoption and use of therapies that became widely available only from late 2019 onward. For example, Darulutamide in combination with docetaxel was approved for mHSPC treatment in 2022, and triplet therapy was recommended in the 2023 ASCO treatment guidelines [<xref rid="cam471176-bib-0035" ref-type="bibr">35</xref>]. Second, our study cohort consisted of older Medicare beneficiaries only. As our analysis focused on older men within the Medicare population, the results may not be directly generalizable to younger adults with early onset PC, who may exhibit distinct PC phenotypes [<xref rid="cam471176-bib-0036" ref-type="bibr">36</xref>, <xref rid="cam471176-bib-0037" ref-type="bibr">37</xref>]. Third, missingness in key clinical variables, such as baseline PSA level and Gleason score, may not be random and could introduce exclusion bias. Finally, the claims&#8208;based algorithm used to identify recurrent mHSPC prioritizes specificity over sensitivity and therefore may miss some mHSPC patients who progressed from a non&#8208;metastatic stage [<xref rid="cam471176-bib-0020" ref-type="bibr">20</xref>]. In contrast, all patients initially diagnosed with metastases will be identified as de novo mHSPC, which may introduce some bias toward positive identification. The absence of repeated measurement of PSA levels may introduce some imprecision in identifying mHSPC. However, as noted by Freedland and colleagues, the imprecision will be insignificant [<xref rid="cam471176-bib-0020" ref-type="bibr">20</xref>]. Additionally, claim&#8208;based sites of metastasis demonstrated limited accuracy, as reported in an old study [<xref rid="cam471176-bib-0035" ref-type="bibr">35</xref>]; however, later studies comparing electronic health records to claims data have reported improved concordance [<xref rid="cam471176-bib-0038" ref-type="bibr">38</xref>].</p></sec><sec sec-type="conclusions" id="cam471176-sec-0022"><label>6</label><title>Conclusion</title><p>Overall, 3 in 10 older men with mHSPC received no systemic drug treatment in 2016&#8211;2020. Although there was a gradual uptake of ARPIs, monotherapy with ADT was still highly prevalent, suggesting the integration of intensified treatment for mHSPC is still suboptimal despite insurance coverage and guideline recommendations. There is a need for targeted interventions to increase the utilization of guideline&#8208;recommended treatments for mHSPC to improve clinical outcomes and reduce racial and socio&#8208;economic disparities in the management of mHSPC.</p></sec><sec id="cam471176-sec-0030"><title>Author Contributions</title><p>
<bold>Bo Zhou:</bold> conceptualization, methodology, data curation, writing &#8211; original draft, writing &#8211; review and editing, formal analysis, visualization, investigation, validation, software. <bold>Amit D. Raval:</bold> funding acquisition, writing &#8211; review and editing, methodology, project administration, investigation, conceptualization, validation. <bold>Yifan Zhang:</bold> formal analysis, writing &#8211; review and editing, visualization, validation, investigation, software. <bold>Matthew J. Korn:</bold> writing &#8211; review and editing, methodology, validation. <bold>Niculae Constantinovici:</bold> writing &#8211; review and editing, validation. <bold>Nethra Sambamoorthi:</bold> formal analysis, writing &#8211; review and editing, software. <bold>Rafia Rasu:</bold> investigation, writing &#8211; review and editing, validation, methodology. <bold>Natasha Littleton:</bold> investigation, writing &#8211; review and editing, validation. <bold>Usha Sambamoorthi:</bold> conceptualization, funding acquisition, methodology, data curation, supervision, writing &#8211; review and editing, writing &#8211; original draft, project administration, resources, software, formal analysis, validation, visualization, investigation.</p></sec><sec sec-type="COI-statement" id="cam471176-sec-0024"><title>Conflicts of Interest</title><p>Author financial disclosure: Amitkumar Raval, Matthew J. Korn, Natasha Littleton, and Niculae Constantinovici are employees and stockholders of Bayer. Bo Zhou, Nethra Sambamoorthi, Rafia Rasu, and Usha Sambamoorthi received research funding from Bayer to conduct the study.</p></sec></body><back><ack id="cam471176-sec-0023"><title>Acknowledgements</title><p>The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section&#160;103885; Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors. We also thank Dr. Mona Pathak for her contributions to initial data analysis.</p></ack><sec sec-type="data-availability" id="cam471176-sec-0026"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from SEER Medicare. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from <ext-link xlink:href="https://healthcaredelivery.cancer.gov/seermedicare/" ext-link-type="uri" specific-use="software is-supplemented-by">https://healthcaredelivery.cancer.gov/seermedicare/</ext-link> with the permission of SEER Medicare.</p></sec><ref-list content-type="cited-references" id="cam471176-bibl-0001"><title>References</title><ref id="cam471176-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cam471176-cit-0001"><string-name name-style="western"><given-names>R. L.</given-names><surname>Siegel</surname></string-name>, <string-name name-style="western"><given-names>K. D.</given-names><surname>Miller</surname></string-name>, <string-name name-style="western"><given-names>N. S.</given-names><surname>Wagle</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Jemal</surname></string-name>, &#8220;<article-title>Cancer Statistics, 2023</article-title>,&#8221; <source>CA: A Cancer Journal for Clinicians</source><volume>73</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>17</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">36633525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21763</pub-id></mixed-citation></ref><ref id="cam471176-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cam471176-cit-0002"><string-name name-style="western"><given-names>K.</given-names><surname>Miller</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Nogueira</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Devasia</surname></string-name>, et&#160;al., &#8220;<article-title>Cancer Treatment and Survivorship Statistics, 2022</article-title>,&#8221; <source>CA: A Cancer Journal for Clinicians</source><volume>72</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>409</fpage>&#8211;<lpage>436</lpage>.<pub-id pub-id-type="pmid">35736631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21731</pub-id></mixed-citation></ref><ref id="cam471176-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam471176-cit-0003"><string-name name-style="western"><given-names>L.</given-names><surname>Gallicchio</surname></string-name>, <string-name name-style="western"><given-names>T. P.</given-names><surname>Devasia</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Tonorezos</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Mollica</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Mariotto</surname></string-name>, &#8220;<article-title>Estimation of the Number of Individuals Living With Metastatic Cancer in the United States</article-title>,&#8221; <source>Journal of the National Cancer Institute</source><volume>114</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>1476</fpage>&#8211;<lpage>1483</lpage>.<pub-id pub-id-type="pmid">35993614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djac158</pub-id><pub-id pub-id-type="pmcid">PMC9949565</pub-id></mixed-citation></ref><ref id="cam471176-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam471176-cit-0004"><string-name name-style="western"><given-names>M. M.</given-names><surname>Desai</surname></string-name>, <string-name name-style="western"><given-names>G. E.</given-names><surname>Cacciamani</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Gill</surname></string-name>, et&#160;al., &#8220;<article-title>Trends in Incidence of Metastatic Prostate Cancer in the US</article-title>,&#8221; <source>JAMA Network Open</source><volume>5</volume>, no. <issue>3</issue> (<year>2022</year>): <elocation-id>e222246</elocation-id>.<pub-id pub-id-type="pmid">35285916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.2246</pub-id><pub-id pub-id-type="pmcid">PMC9907338</pub-id></mixed-citation></ref><ref id="cam471176-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam471176-cit-0005"><string-name name-style="western"><given-names>A. B.</given-names><surname>Weiner</surname></string-name>, <string-name name-style="western"><given-names>R. S.</given-names><surname>Matulewicz</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Eggener</surname></string-name>, and <string-name name-style="western"><given-names>E. M.</given-names><surname>Schaeffer</surname></string-name>, &#8220;<article-title>Increasing Incidence of Metastatic Prostate Cancer in the United States (2004&#8211;2013)</article-title>,&#8221; <source>Prostate Cancer and Prostatic Diseases</source><volume>19</volume>, no. <issue>4</issue> (<year>2016</year>): <fpage>395</fpage>&#8211;<lpage>397</lpage>.<pub-id pub-id-type="pmid">27431496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/pcan.2016.30</pub-id></mixed-citation></ref><ref id="cam471176-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam471176-cit-0006"><string-name name-style="western"><given-names>A. S.</given-names><surname>Merseburger</surname></string-name>, <string-name name-style="western"><given-names>L. M.</given-names><surname>Krabbe</surname></string-name>, <string-name name-style="western"><given-names>B. J.</given-names><surname>Krause</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Bohmer</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Perner</surname></string-name>, and <string-name name-style="western"><given-names>G. V.</given-names><surname>Amsberg</surname></string-name>, &#8220;<article-title>The Treatment of Metastatic, Hormone&#8208;Sensitive Prostatic Carcinoma</article-title>,&#8221; <source>Deutsches &#196;rzteblatt International</source><volume>119</volume>, no. <issue>37</issue> (<year>2022</year>): <fpage>622</fpage>&#8211;<lpage>632</lpage>.<pub-id pub-id-type="pmid">35912436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3238/arztebl.m2022.0294</pub-id><pub-id pub-id-type="pmcid">PMC9756320</pub-id></mixed-citation></ref><ref id="cam471176-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cam471176-cit-0007"><string-name name-style="western"><given-names>K.</given-names><surname>Ng</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Smith</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Shamash</surname></string-name>, &#8220;<article-title>Metastatic Hormone&#8208;Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First&#8208;Line Setting</article-title>,&#8221; <source>Oncology and Therapy</source><volume>8</volume>, no. <issue>2</issue> (<year>2020</year>): <fpage>209</fpage>&#8211;<lpage>230</lpage>.<pub-id pub-id-type="pmid">32700045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40487-020-00119-z</pub-id><pub-id pub-id-type="pmcid">PMC7683690</pub-id></mixed-citation></ref><ref id="cam471176-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cam471176-cit-0008"><string-name name-style="western"><given-names>C. J.</given-names><surname>Sweeney</surname></string-name>, <string-name name-style="western"><given-names>Y. H.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Carducci</surname></string-name>, et&#160;al., &#8220;<article-title>Chemohormonal Therapy in Metastatic Hormone&#8208;Sensitive Prostate Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>373</volume>, no. <issue>8</issue> (<year>2015</year>): <fpage>737</fpage>&#8211;<lpage>746</lpage>.<pub-id pub-id-type="pmid">26244877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1503747</pub-id><pub-id pub-id-type="pmcid">PMC4562797</pub-id></mixed-citation></ref><ref id="cam471176-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cam471176-cit-0009"><string-name name-style="western"><given-names>N. D.</given-names><surname>James</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Sydes</surname></string-name>, <string-name name-style="western"><given-names>N. W.</given-names><surname>Clarke</surname></string-name>, et&#160;al., &#8220;<article-title>Addition of Docetaxel, Zoledronic Acid, or Both to First&#8208;Line Long&#8208;Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results From an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial</article-title>,&#8221; <source>Lancet</source><volume>387</volume>, no. <issue>10024</issue> (<year>2016</year>): <fpage>1163</fpage>&#8211;<lpage>1177</lpage>.<pub-id pub-id-type="pmid">26719232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)01037-5</pub-id><pub-id pub-id-type="pmcid">PMC4800035</pub-id></mixed-citation></ref><ref id="cam471176-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam471176-cit-0010"><string-name name-style="western"><given-names>K.</given-names><surname>Fizazi</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Tran</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Fein</surname></string-name>, et&#160;al., &#8220;<article-title>Abiraterone Plus Prednisone in Metastatic, Castration&#8208;Sensitive Prostate Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>377</volume>, no. <issue>4</issue> (<year>2017</year>): <fpage>352</fpage>&#8211;<lpage>360</lpage>.<pub-id pub-id-type="pmid">28578607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1704174</pub-id></mixed-citation></ref><ref id="cam471176-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam471176-cit-0011"><string-name name-style="western"><given-names>I. D.</given-names><surname>Davis</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Martin</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Stockler</surname></string-name>, et&#160;al., &#8220;<article-title>Enzalutamide With Standard First&#8208;Line Therapy in Metastatic Prostate Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>381</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>121</fpage>&#8211;<lpage>131</lpage>.<pub-id pub-id-type="pmid">31157964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1903835</pub-id></mixed-citation></ref><ref id="cam471176-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam471176-cit-0012"><string-name name-style="western"><given-names>A. J.</given-names><surname>Armstrong</surname></string-name>, <string-name name-style="western"><given-names>R. Z.</given-names><surname>Szmulewitz</surname></string-name>, <string-name name-style="western"><given-names>D. P.</given-names><surname>Petrylak</surname></string-name>, et&#160;al., &#8220;<article-title>ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone&#8208;Sensitive Prostate Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>37</volume>, no. <issue>32</issue> (<year>2019</year>): <fpage>2974</fpage>&#8211;<lpage>2986</lpage>.<pub-id pub-id-type="pmid">31329516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.19.00799</pub-id><pub-id pub-id-type="pmcid">PMC6839905</pub-id></mixed-citation></ref><ref id="cam471176-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam471176-cit-0013"><string-name name-style="western"><given-names>K.</given-names><surname>Fizazi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Foulon</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Carles</surname></string-name>, et&#160;al., &#8220;<article-title>Abiraterone Plus Prednisone Added to Androgen Deprivation Therapy and Docetaxel in de Novo Metastatic Castration&#8208;Sensitive Prostate Cancer (PEACE&#8208;1): A Multicentre, Open&#8208;Label, Randomised, Phase 3 Study With a 2 &#215;&#8201;2 Factorial Design</article-title>,&#8221; <source>Lancet</source><volume>399</volume>, no. <issue>10336</issue> (<year>2022</year>): <fpage>1695</fpage>&#8211;<lpage>1707</lpage>.<pub-id pub-id-type="pmid">35405085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(22)00367-1</pub-id></mixed-citation></ref><ref id="cam471176-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam471176-cit-0014"><string-name name-style="western"><given-names>M. R.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hussain</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Saad</surname></string-name>, et&#160;al., &#8220;<article-title>Darolutamide and Survival in Metastatic, Hormone&#8208;Sensitive Prostate Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>386</volume>, no. <issue>12</issue> (<year>2022</year>): <fpage>1132</fpage>&#8211;<lpage>1142</lpage>.<pub-id pub-id-type="pmid">35179323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2119115</pub-id><pub-id pub-id-type="pmcid">PMC9844551</pub-id></mixed-citation></ref><ref id="cam471176-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cam471176-cit-0015"><string-name name-style="western"><given-names>L.</given-names><surname>Kostos</surname></string-name> and <string-name name-style="western"><given-names>D. G.</given-names><surname>Murphy</surname></string-name>, &#8220;<article-title>Treatment Options for Metastatic Hormone&#8208;Sensitive Prostate Cancer</article-title>,&#8221; <source>Lancet Oncology</source><volume>23</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>1234</fpage>&#8211;<lpage>1235</lpage>.<pub-id pub-id-type="pmid">36075259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00520-4</pub-id></mixed-citation></ref><ref id="cam471176-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cam471176-cit-0016"><string-name name-style="western"><given-names>E. M.</given-names><surname>Schaeffer</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Srinivas</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Adra</surname></string-name>, et&#160;al., &#8220;<article-title>NCCN Guidelines(R) Insights: Prostate Cancer, Version 1.2023</article-title>,&#8221; <source>Journal of the National Comprehensive Cancer Network</source><volume>20</volume>, no. <issue>12</issue> (<year>2022</year>): <fpage>1288</fpage>&#8211;<lpage>1298</lpage>.<pub-id pub-id-type="pmid">36509074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2022.0063</pub-id></mixed-citation></ref><ref id="cam471176-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam471176-cit-0017"><string-name name-style="western"><given-names>C. J.</given-names><surname>Ryan</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Ke</surname></string-name>, <string-name name-style="western"><given-names>M. H.</given-names><surname>Lafeuille</surname></string-name>, et&#160;al., &#8220;<article-title>Management of Patients With Metastatic Castration&#8208;Sensitive Prostate Cancer in the Real&#8208;World Setting in the United States</article-title>,&#8221; <source>Journal of Urology</source><volume>206</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>1420</fpage>&#8211;<lpage>1429</lpage>.<pub-id pub-id-type="pmid">34293915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JU.0000000000002121</pub-id><pub-id pub-id-type="pmcid">PMC8584208</pub-id></mixed-citation></ref><ref id="cam471176-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam471176-cit-0018"><string-name name-style="western"><given-names>S. J.</given-names><surname>Freedland</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Sandin</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Sah</surname></string-name>, et&#160;al., &#8220;<article-title>Treatment Patterns and Survival in Metastatic Castration&#8208;Sensitive Prostate Cancer in the US Veterans Health Administration</article-title>,&#8221; <source>Cancer Medicine</source><volume>10</volume>, no. <issue>23</issue> (<year>2021</year>): <fpage>8570</fpage>&#8211;<lpage>8580</lpage>.<pub-id pub-id-type="pmid">34725947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.4372</pub-id><pub-id pub-id-type="pmcid">PMC8633245</pub-id></mixed-citation></ref><ref id="cam471176-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam471176-cit-0019"><string-name name-style="western"><given-names>E. I.</given-names><surname>Heath</surname></string-name>, <string-name name-style="western"><given-names>G. E.</given-names><surname>Dyson</surname></string-name>, <string-name name-style="western"><given-names>F. C.</given-names><surname>Cackowski</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Hafron</surname></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Powell</surname></string-name>, &#8220;<article-title>Treatment Intensification Patterns and Utilization in Patients With Metastatic Castration&#8208;Sensitive Prostate Cancer</article-title>,&#8221; <source>Clinical Genitourinary Cancer</source><volume>20</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>524</fpage>&#8211;<lpage>532</lpage>.<pub-id pub-id-type="pmid">35864053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clgc.2022.06.017</pub-id></mixed-citation></ref><ref id="cam471176-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cam471176-cit-0020"><string-name name-style="western"><given-names>S. J.</given-names><surname>Freedland</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Ke</surname></string-name>, <string-name name-style="western"><given-names>M. H.</given-names><surname>Lafeuille</surname></string-name>, et&#160;al., &#8220;<article-title>Identification of Patients With Metastatic Castration&#8208;Sensitive or Metastatic Castration&#8208;Resistant Prostate Cancer Using Administrative Health Claims and Laboratory Data</article-title>,&#8221; <source>Current Medical Research and Opinion</source><volume>37</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>609</fpage>&#8211;<lpage>622</lpage>.<pub-id pub-id-type="pmid">33476184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03007995.2021.1879753</pub-id></mixed-citation></ref><ref id="cam471176-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cam471176-cit-0021"><string-name name-style="western"><given-names>T.</given-names><surname>van Elst</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Mehra</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bloem</surname></string-name>, et&#160;al., &#8220;<article-title>The Conundrum of Treating de Novo Metastatic Hormone&#8208;Sensitive Prostate Cancer</article-title>,&#8221; <source>Scientific Reports</source><volume>15</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>12500</fpage>.<pub-id pub-id-type="pmid">40216859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-025-96065-9</pub-id><pub-id pub-id-type="pmcid">PMC11992181</pub-id></mixed-citation></ref><ref id="cam471176-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cam471176-cit-0022"><string-name name-style="western"><given-names>J.</given-names><surname>Partridge</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Rege</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>HSD48 Real World Treatment Patterns Among US&#8208;Based Metastatic Hormone Sensitive Prostate Cancer (MHSPC) Patients: Results From Syndicated Chart Reviews</article-title>,&#8221; <source>Value in Health</source><volume>25</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>S488</fpage>.</mixed-citation></ref><ref id="cam471176-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cam471176-cit-0023"><string-name name-style="western"><given-names>C.</given-names><surname>Eule</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Kuna</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Robin</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Gershman</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Flaig</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Kim</surname></string-name>, &#8220;<article-title>Treatment Intensification in Metastatic Hormone&#8208;Sensitive Prostate Cancer: An Analysis of Real&#8208;World Practice Patterns From the CancerLinQ Database</article-title>,&#8221; <source>Urologic Oncology: Seminars and Original Investigations</source><volume>42</volume>, no. <issue>12</issue> (<year>2024</year>): <fpage>447</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urolonc.2024.07.002</pub-id><pub-id pub-id-type="pmcid">PMC11573622</pub-id><pub-id pub-id-type="pmid">39191549</pub-id></mixed-citation></ref><ref id="cam471176-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cam471176-cit-0024"><string-name name-style="western"><given-names>A. D.</given-names><surname>Raval</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Korn</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Constantinovici</surname></string-name>, &#8220;<article-title>Real&#8208;World Utilization Patterns of Radium&#8208;223 in Metastatic Prostate Cancer in the United States: An Administrative Claims Database Study</article-title>,&#8221; <source>Age (Dordrecht, Netherlands)</source><volume>68</volume>, no. <issue>61</issue> (<year>2024</year>): <fpage>77</fpage>.</mixed-citation></ref><ref id="cam471176-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cam471176-cit-0025"><string-name name-style="western"><given-names>T. M.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Agarwal</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Mahal</surname></string-name>, et&#160;al., &#8220;<article-title>Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer</article-title>,&#8221; <source>JAMA Network Open</source><volume>6</volume>, no. <issue>12</issue> (<year>2023</year>): <elocation-id>e2345906</elocation-id>.<pub-id pub-id-type="pmid">38039002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.45906</pub-id><pub-id pub-id-type="pmcid">PMC10692845</pub-id></mixed-citation></ref><ref id="cam471176-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cam471176-cit-0026"><string-name name-style="western"><given-names>M. V.</given-names><surname>Caram</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Oerline</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dusetzina</surname></string-name>, et&#160;al., &#8220;<article-title>Financial Hardship Among Medicare Beneficiaries Prescribed Oral Targeted Therapies for Advanced Prostate Cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>38</volume> (<year>2020</year>): <fpage>68</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.33176</pub-id><pub-id pub-id-type="pmcid">PMC7959094</pub-id><pub-id pub-id-type="pmid">32926427</pub-id></mixed-citation></ref><ref id="cam471176-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cam471176-cit-0027"><string-name name-style="western"><given-names>M.</given-names><surname>Kyle</surname></string-name> and <string-name name-style="western"><given-names>N.</given-names><surname>Keating</surname></string-name>, &#8220;<article-title>Prior Authorization and Association With Delayed or Discontinued Prescription Fills</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>8</issue> (<year>2024</year>): <fpage>951</fpage>&#8211;<lpage>960</lpage>.<pub-id pub-id-type="pmid">38086013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.01693</pub-id><pub-id pub-id-type="pmcid">PMC10927330</pub-id></mixed-citation></ref><ref id="cam471176-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cam471176-cit-0028"><string-name name-style="western"><given-names>D.</given-names><surname>Samoil</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Fox</surname></string-name>, and <string-name name-style="western"><given-names>J. K.</given-names><surname>Papadakos</surname></string-name>, &#8220;<article-title>The Importance of Health Literacy on Clinical Cancer Outcomes: A Scoping Review</article-title>,&#8221; <source>Annals of Cancer Epidemiology</source><volume>5</volume> (<year>2021</year>): <elocation-id>5</elocation-id>.</mixed-citation></ref><ref id="cam471176-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cam471176-cit-0029"><string-name name-style="western"><given-names>N.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>C. B.</given-names><surname>McGrath</surname></string-name>, <string-name name-style="western"><given-names>B. A.</given-names><surname>Dickerman</surname></string-name>, <string-name name-style="western"><given-names>R. C.</given-names><surname>Nethery</surname></string-name>, and <string-name name-style="western"><given-names>L. A.</given-names><surname>Mucci</surname></string-name>, &#8220;<article-title>Abstract 2255: Social Support with Physical and Psychosocial Quality of Life in Individuals with Prostate Cancer in the Health Professionals Follow&#8208;Up Study (HPFS)</article-title>,&#8221; <source>Cancer Research</source><volume>84</volume>, no. <issue>6_Suppl</issue> (<year>2024</year>): <fpage>2255</fpage>&#8211;<lpage>2255</lpage>.</mixed-citation></ref><ref id="cam471176-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cam471176-cit-0030"><string-name name-style="western"><given-names>S.</given-names><surname>Aneja</surname></string-name> and <string-name name-style="western"><given-names>J. B.</given-names><surname>Yu</surname></string-name>, &#8220;<article-title>The Impact of County&#8208;Level Radiation Oncologist Density on Prostate Cancer Mortality in the United States</article-title>,&#8221; <source>Prostate Cancer and Prostatic Diseases</source><volume>15</volume>, no. <issue>4</issue> (<year>2012</year>): <fpage>391</fpage>&#8211;<lpage>396</lpage>.<pub-id pub-id-type="pmid">22824828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/pcan.2012.28</pub-id></mixed-citation></ref><ref id="cam471176-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cam471176-cit-0031"><string-name name-style="western"><given-names>J. W.</given-names><surname>Lillard</surname>, <suffix>Jr.</suffix></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Moses</surname></string-name>, <string-name name-style="western"><given-names>B. A.</given-names><surname>Mahal</surname></string-name>, and <string-name name-style="western"><given-names>D. J.</given-names><surname>George</surname></string-name>, &#8220;<article-title>Racial Disparities in B Lack Men With Prostate Cancer: A Literature Review</article-title>,&#8221; <source>Cancer</source><volume>128</volume>, no. <issue>21</issue> (<year>2022</year>): <fpage>3787</fpage>&#8211;<lpage>3795</lpage>.<pub-id pub-id-type="pmid">36066378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.34433</pub-id><pub-id pub-id-type="pmcid">PMC9826514</pub-id></mixed-citation></ref><ref id="cam471176-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cam471176-cit-0032"><string-name name-style="western"><given-names>M. C.</given-names><surname>DeRouen</surname></string-name>, <string-name name-style="western"><given-names>C. W.</given-names><surname>Schupp</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Koo</surname></string-name>, et&#160;al., &#8220;<article-title>Impact of Individual and Neighborhood Factors on Disparities in Prostate Cancer Survival</article-title>,&#8221; <source>Cancer Epidemiology</source><volume>53</volume> (<year>2018</year>): <fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">29328959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canep.2018.01.003</pub-id><pub-id pub-id-type="pmcid">PMC7499899</pub-id></mixed-citation></ref><ref id="cam471176-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cam471176-cit-0033"><string-name name-style="western"><given-names>B. D.</given-names><surname>Cortese</surname></string-name>, <string-name name-style="western"><given-names>S. B.</given-names><surname>Dusetzina</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Hussein Al Awamlh</surname></string-name>, et&#160;al., &#8220;<article-title>Estimating the Impact of the Inflation Reduction Act on the Out&#8208;Of&#8208;Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer</article-title>,&#8221; <source>Urology Practice</source><volume>10</volume>, no. <issue>5</issue> (<year>2023</year>): <fpage>476</fpage>&#8211;<lpage>483</lpage>.<pub-id pub-id-type="pmid">37409930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/UPJ.0000000000000425</pub-id></mixed-citation></ref><ref id="cam471176-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cam471176-cit-0034"><string-name name-style="western"><given-names>K.</given-names><surname>Malshy</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Golijanin</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Khaleel</surname></string-name>, et&#160;al., &#8220;<article-title>Navigating Management of Localized Prostate Cancer in the Geriatric Population</article-title>,&#8221; <source>Critical Reviews in Oncology/Hematology</source><volume>206</volume> (<year>2025</year>): <elocation-id>104600</elocation-id>.<pub-id pub-id-type="pmid">39709068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2024.104600</pub-id></mixed-citation></ref><ref id="cam471176-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cam471176-cit-0035"><string-name name-style="western"><given-names>E.</given-names><surname>Onukwugha</surname></string-name>, <string-name name-style="western"><given-names>C. D.</given-names><surname>Mullins</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Yong</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>McNally</surname></string-name>, <string-name name-style="western"><given-names>B. S.</given-names><surname>Seal</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Hussain</surname></string-name>, &#8220;<article-title>Bone Metastasis (BM) Based on SEER Registry Versus Medicare Claims Among Metastatic Prostate Cancer (PCa) Patients (Pts) in SEER&#8208;Medicare</article-title>,&#8221; <source>American Society of Clinical Oncology</source><volume>30</volume> (<year>2012</year>): <elocation-id>e15148</elocation-id>.</mixed-citation></ref><ref id="cam471176-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cam471176-cit-0036"><string-name name-style="western"><given-names>C. A.</given-names><surname>Salinas</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Tsodikov</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ishak&#8208;Howard</surname></string-name>, and <string-name name-style="western"><given-names>K. A.</given-names><surname>Cooney</surname></string-name>, &#8220;<article-title>Prostate Cancer in Young Men: An Important Clinical Entity</article-title>,&#8221; <source>Nature Reviews Urology</source><volume>11</volume>, no. <issue>6</issue> (<year>2014</year>): <fpage>317</fpage>&#8211;<lpage>323</lpage>, <pub-id pub-id-type="doi">10.1038/nrurol.2014.91</pub-id>.<pub-id pub-id-type="pmid">24818853</pub-id><pub-id pub-id-type="pmcid">PMC4191828</pub-id></mixed-citation></ref><ref id="cam471176-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cam471176-cit-0037"><string-name name-style="western"><given-names>A.</given-names><surname>Bleyer</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Spreafico</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Barr</surname></string-name>, &#8220;<article-title>Prostate Cancer in Young Men: An Emerging Young Adult and Older Adolescent Challenge</article-title>,&#8221; <source>Cancer</source><volume>126</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>46</fpage>&#8211;<lpage>57</lpage>, <pub-id pub-id-type="doi">10.1002/cncr.32498</pub-id>.<pub-id pub-id-type="pmid">31553489</pub-id></mixed-citation></ref><ref id="cam471176-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cam471176-cit-0038"><string-name name-style="western"><given-names>N.</given-names><surname>Sathiakumar</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Delzell</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yun</surname></string-name>, et&#160;al., &#8220;<article-title>Accuracy of Medicare Claim&#8211;Based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases</article-title>,&#8221; <source>Medical Care</source><volume>55</volume>, no. <issue>12</issue> (<year>2017</year>): <fpage>e144</fpage>&#8211;<lpage>e149</lpage>.<pub-id pub-id-type="pmid">29135778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0000000000000539</pub-id></mixed-citation></ref></ref-list><app-group><app id="cam471176-app-0001" content-type="Appendix"><label>Appendix 1</label><title>Cohort Selection</title><p>
<table-wrap position="anchor" id="jats-table-wrap-1" orientation="portrait"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Steps</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cohort selection criteria</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sample size</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Incident Primary Prostate Cancer (PC) from SEER Registry Data 2008&#8211;2019</td><td align="center" valign="top" rowspan="1" colspan="1">655,074</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Metastatic PC (mPC) identified from SEER Registry or Medicare Claims Jul 2016&#8208; Dec 2019</td><td align="center" valign="top" rowspan="1" colspan="1">36,414</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">Alive 6&#8201;months after initial mPC diagnosis and eligible to receive curative cancer care</td><td align="center" valign="top" rowspan="1" colspan="1">30,078</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">Castration na&#239;ve or ICD&#8208;code for hormone sensitivity (Z19.1)</td><td align="center" valign="top" rowspan="1" colspan="1">25,047</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Confirmed hormone sensitivity from Medicare claims, and received no treatment for metastatic castration&#8208;resistant PC (mCRPC)</td><td align="center" valign="top" rowspan="1" colspan="1">24,575</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">Age 67 or above at metastatic Hormone Sensitive PC (mHSPC) diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">19,671</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">Continuous enrollment in fee&#8208;for&#8208;service (FFS) Parts A/B/D 12&#8201;months prior to and 6&#8201;months after mHSPC diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">6850</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7a</td><td align="center" valign="top" rowspan="1" colspan="1">Received systemic treatment within 6&#8201;months after mHSPC diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">4769</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7b</td><td align="center" valign="top" rowspan="1" colspan="1">Treated with ADT</td><td align="center" valign="top" rowspan="1" colspan="1">4681</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7c</td><td align="center" valign="top" rowspan="1" colspan="1">Treated with ADT but without triplet therapy</td><td align="center" valign="top" rowspan="1" colspan="1">4645</td></tr></tbody></table><table-wrap-foot id="cam471176-ntgp-0005"><fn id="cam471176-note-0011"><p>Abbreviations: ADT, androgen deprivation therapy; ICD&#8208;10&#8208;CM, International Classification of Diseases 10th revision, clinical modification; mCRPC, metastatic castration&#8208;resistant prostate cancer; mHSPC, metastatic hormone&#8208;sensitive prostate cancer; mPC, metastatic prostate cancer.</p></fn></table-wrap-foot></table-wrap>
</p></app><app id="cam471176-app-0002" content-type="Appendix"><label>Appendix 2</label><title>Algorithm to Identify Men With mHSPC</title><p>Recurrent mHSPC will be identified based on the first metastasis Medicare claim for men initially registered with non&#8208;metastatic PC (AJCC stage I&#8211;III or M0 stage) in the SEER registry, using the published algorithm by Freedland et&#160;al. [<xref rid="cam471176-bib-0034" ref-type="bibr">34</xref>]:</p><p>Step 1: Establish Index Date.
<list list-type="bullet" id="cam471176-list-0001"><list-item id="cam471176-li-0001"><p>Identify metastatic disease (ICD&#8208;9: 196.xx&#8208;199.1x, 209.7x, ICD10&#8208; C77. xx.&#8208;C80.0x, C7B) to establish index date.</p></list-item><list-item id="cam471176-li-0002"><p>The index date is the first observed date associated with metastatic disease after PC diagnosis.</p></list-item></list>
</p><p>Step 2: Identify Hormone sensitivity (Satisfy any one of the criteria).
<list list-type="bullet" id="cam471176-list-0002"><list-item id="cam471176-li-0003"><p>Criterion #1: Identify hormone sensitivity (&#8805;&#8201;1 claim with ICD10 (ICD&#8208;10&#8208;CM Z19.1)) in 12&#8208;month window prior to index date.</p></list-item><list-item id="cam471176-li-0004"><p>Criterion #2: Hormone/castration naive, defined as no claim for surgical or medical castration within 18&#8201;months before the index date.</p></list-item></list>
</p><p>Step 3: Confirm Hormone sensitivity: Exclude those with any of the following criteria.
<list list-type="bullet" id="cam471176-list-0003"><list-item id="cam471176-li-0005"><p>Criterion #1: Diagnosis code (ICD&#8208;10: CM Z19.2) indicating hormone resistance during the mHSPC identification period.</p></list-item><list-item id="cam471176-li-0006"><p>Criterion #2: Rising PSA levels (ICD&#8208;10 CM R97.21) following surgical castration during the mHSPC identification period.</p></list-item><list-item id="cam471176-li-0007"><p>Criterion #3: Rising PSA levels (ICD&#8208;10 CM R97.21) following medical castration during the mHSPC identification period. Medical castration is defined as &#8805;&#8201;90&#8201;days of continuous ADT use.</p></list-item><list-item id="cam471176-li-0008"><p>Criterion #4: Had surgical castration at least 90&#8201;days prior to the index date.</p></list-item><list-item id="cam471176-li-0009"><p>Criterion #5: Had continuous ADT throughout 90&#8201;days (with no gap &gt;&#8201;30&#8201;days) prior to the index date. HCPCS J codes, dosage designation (1, 3, 4) from the NCH files or revenue center unit count from OUTSAF files will be used to calculate hormone therapy for men with prostate cancer as per guidance from SEER (<ext-link xlink:href="https://healthcaredelivery.cancer.gov/seermedicare/considerations/prostate.html" ext-link-type="uri">https://healthcaredelivery.cancer.gov/seermedicare/considerations/prostate.html</ext-link>).</p></list-item><list-item id="cam471176-li-0010"><p>Criterion #6: &#8805;&#8201;1 claim of the following medications use&#8212;Pembrolizumab, Sipuleucel&#8208;T, Radium&#8208;223, Lutetium Lu 177 vipivotide tetraxetan, Rucaparib, Olaparib, abiraterone before 02/2018, enzalutamide before 12/2019) prior to the index date.</p></list-item></list>
</p></app><app id="cam471176-app-0003" content-type="Appendix"><label>Appendix 3</label><title>Number of Months to Next Non&#8208;Index Therapy</title><p>
<table-wrap position="anchor" id="jats-table-wrap-2" orientation="portrait"><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="7" valign="bottom" rowspan="1">Older adults (age&#8201;&#8805;&#8201;67&#8201;years) with mHSPC</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="7" valign="bottom" rowspan="1">SEER&#8208;medicare linked database (2015&#8211;2020)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Overall cohort</th><th align="center" valign="bottom" rowspan="1" colspan="1">ADT only</th><th align="center" valign="bottom" rowspan="1" colspan="1">ADT&#8201;+&#8201;Docetaxel</th><th align="center" valign="bottom" rowspan="1" colspan="1">ADT&#8201;+&#8201;ARPI</th><th align="center" valign="bottom" rowspan="1" colspan="1">ADT+ ABI</th><th align="center" valign="bottom" rowspan="1" colspan="1">ADT+ ENZA</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Cohort size</td><td align="center" valign="top" rowspan="1" colspan="1">4645</td><td align="center" valign="top" rowspan="1" colspan="1">3225</td><td align="center" valign="top" rowspan="1" colspan="1">403</td><td align="center" valign="top" rowspan="1" colspan="1">1017</td><td align="center" valign="top" rowspan="1" colspan="1">827</td><td align="center" valign="top" rowspan="1" colspan="1">148</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of individuals received non&#8208;index therapy</td><td align="center" valign="top" rowspan="1" colspan="1">1526</td><td align="center" valign="top" rowspan="1" colspan="1">1028</td><td align="center" valign="top" rowspan="1" colspan="1">217</td><td align="center" valign="top" rowspan="1" colspan="1">281</td><td align="center" valign="top" rowspan="1" colspan="1">242</td><td align="center" valign="top" rowspan="1" colspan="1">32</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Time to next treatment in months</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ARPIs</td><td align="center" valign="top" rowspan="1" colspan="1">13.36</td><td align="center" valign="top" rowspan="1" colspan="1">14.03</td><td align="center" valign="top" rowspan="1" colspan="1">12.47</td><td align="center" valign="top" rowspan="1" colspan="1">11.25</td><td align="center" valign="top" rowspan="1" colspan="1">11.40</td><td align="center" valign="top" rowspan="1" colspan="1">11.24</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Abiraterone</td><td align="center" valign="top" rowspan="1" colspan="1">14.38</td><td align="center" valign="top" rowspan="1" colspan="1">14.92</td><td align="center" valign="top" rowspan="1" colspan="1">12.85</td><td align="center" valign="top" rowspan="1" colspan="1">11.24</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">11.24</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Apalutamide</td><td align="center" valign="top" rowspan="1" colspan="1">17.58</td><td align="center" valign="top" rowspan="1" colspan="1">19.08</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">11.92</td><td align="center" valign="top" rowspan="1" colspan="1">11.92</td><td align="center" valign="top" rowspan="1" colspan="1">##</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Darolutamide</td><td align="center" valign="top" rowspan="1" colspan="1">24.07</td><td align="center" valign="top" rowspan="1" colspan="1">27.32</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Enzalutamide</td><td align="center" valign="top" rowspan="1" colspan="1">14.87</td><td align="center" valign="top" rowspan="1" colspan="1">15.54</td><td align="center" valign="top" rowspan="1" colspan="1">16.90</td><td align="center" valign="top" rowspan="1" colspan="1">11.52</td><td align="center" valign="top" rowspan="1" colspan="1">11.68</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment patterns among men with mCRPC</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of individuals who progressed to mCRPC</td><td align="center" valign="top" rowspan="1" colspan="1">1358</td><td align="center" valign="top" rowspan="1" colspan="1">886</td><td align="center" valign="top" rowspan="1" colspan="1">169</td><td align="center" valign="top" rowspan="1" colspan="1">303</td><td align="center" valign="top" rowspan="1" colspan="1">249</td><td align="center" valign="top" rowspan="1" colspan="1">44</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of individuals received non&#8208;index therapy</td><td align="center" valign="top" rowspan="1" colspan="1">783</td><td align="center" valign="top" rowspan="1" colspan="1">507</td><td align="center" valign="top" rowspan="1" colspan="1">117</td><td align="center" valign="top" rowspan="1" colspan="1">159</td><td align="center" valign="top" rowspan="1" colspan="1">139</td><td align="center" valign="top" rowspan="1" colspan="1">18</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Time to next treatment in months</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ARPI</td><td align="center" valign="top" rowspan="1" colspan="1">14.04</td><td align="center" valign="top" rowspan="1" colspan="1">14.65</td><td align="center" valign="top" rowspan="1" colspan="1">12.70</td><td align="center" valign="top" rowspan="1" colspan="1">12.83</td><td align="center" valign="top" rowspan="1" colspan="1">12.95</td><td align="center" valign="top" rowspan="1" colspan="1">##</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Abiraterone</td><td align="center" valign="top" rowspan="1" colspan="1">15.40</td><td align="center" valign="top" rowspan="1" colspan="1">16.07</td><td align="center" valign="top" rowspan="1" colspan="1">13.45</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">##</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Apalutamide</td><td align="center" valign="top" rowspan="1" colspan="1">20.28</td><td align="center" valign="top" rowspan="1" colspan="1">20.61</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Darolutamide</td><td align="center" valign="top" rowspan="1" colspan="1">27.01</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td><td align="center" valign="top" rowspan="1" colspan="1">##</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Enzalutamide</td><td align="center" valign="top" rowspan="1" colspan="1">16.00</td><td align="center" valign="top" rowspan="1" colspan="1">16.42</td><td align="center" valign="top" rowspan="1" colspan="1">18.44</td><td align="center" valign="top" rowspan="1" colspan="1">13.01</td><td align="center" valign="top" rowspan="1" colspan="1">12.78</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot id="cam471176-ntgp-0006"><fn id="cam471176-note-0012"><p>
<italic toggle="yes">Note:</italic> ## indicates cell sizes &lt;&#8201;11 and suppressed as per CMS policy.</p></fn><fn id="cam471176-note-0013"><p>Abbreviation: NA, not applicable.</p></fn></table-wrap-foot></table-wrap>
</p></app></app-group></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>